



BR

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 99/52879
C07D 239/12, 407/12, 239/42, 207/22, 223/12, C07C 279/14, C07D 213/81, 213/82, 307/68, C07C 275/16, C07D 403/12, A61K 31/505, 31/41, 31/155, 31/17			(43) International Publication Date:	21 October 1999 (21.10.99)
(21) International Application Number:	PCT/US99/08180		(81) Designated States:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	14 April 1999 (14.04.99)		(30) Priority Data:	
09/059,579	14 April 1998 (14.04.98)	US	(71) Applicant:	AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).
(72) Inventors:	KEES, Kenneth, Lewis; 147 Finney Road, Glenmoore, PA 19343 (US). GARRICK, Lloyd, Michael; 117 Mill Grove Drive, Norristown, PA 19403 (US). GOPAL-SAMY, Ariamala; 1106 Devon Court, Mahwah, NJ 07430 (US).		(74) Agents:	BARRETT, Rebecca, R.; American Home Products Corporation, Patent Law Dept. – 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.
(54) Title: ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS				
<p style="text-align: right;">(I)</p>				
(57) Abstract				
Compounds of formula (I) are useful in the treatment of various disorders including, but not limited to, cancer, angiogenesis, restenosis, inflammation, bone diseases, and as antiviral agents. Novel methods of making compounds of formula (I) are also provided.				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon			PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

-1-

ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS

5

Background of Invention

The integrin $\alpha_v\beta_3$ has been shown to mediate the invasion of cancerous melanoma cells into healthy tissue (Sefton et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 1557-1561) and to protect these cells against natural cell death cycle (apoptosis) (Montgomery et al., Proc. Natl. Acad. Sci. USA, 1994, 91, 8856-8860). Vitronectin receptor ($\alpha_v\beta_3$) antagonists have been shown to inhibit the growth of various solid tumors of human origin (Brooks et al., Cell, 1994, 79, 1157-1164). More recently, $\alpha_v\beta_3$ has been shown to be involved in liver metastasis (Yun et al., Cancer Res., 1996, 56, 3103-3111).

Although angiogenesis is an important and natural process in growth and wound healing, it is now appreciated that a variety of clinically relevant conditions are pathologically related to these processes, and that the integrin $\alpha_v\beta_3$ is involved. For example, $\alpha_v\beta_3$ was shown to be expressed on human wound tissue but not on normal skin (Brooks, et al., Science, 1994, 264, 569-571) and is preferentially expressed on angiogenic blood vessels, such as those feeding a growing/invasive tumor. It has also been shown that antagonists of $\alpha_v\beta_3$ promote tumor regression by inducing apoptosis of the tumor cells (Brooks et al., Cell, 1994, 79, 1157-1164). This process of neovascularization which is critical for tumor growth and metastasis, is also an important event in ocular tissue, leading to diabetic retinopathy, glaucoma and blindness (Adonis et al., Am. J. Ophthal., 1994, 118, 445-450; Hammes et al., Nature Med., 1996, 2, 529-533; Friedlander, et al., Natl. Acad. Sci. U.S.A., 1996, 93, 9764-

-2-

9769) and in joints, promoting rheumatoid arthritis (Peacock et al., J. Exp. Med., 1992, 175, 1135-1138).

$\alpha_v\beta_3$ has been shown to play a pivotal role in the proliferation and migration of smooth muscle and vascular endothelial cells, a pathological process leading to 5 restenosis after balloon angioplasty (Choi et al., J. Vasc. Surgery, 1994, 19, 125-134; Matsumo et al., Circulation, 1994, 90, 2203-2206). At least one type of virus (adenovirus) has been shown to utilize $\alpha_v\beta_3$ for entering host cells (White et al., Current Biology, 1993, 596-599).

Various bone diseases involve bone resorption which is mediated by only one 10 known class of cells, the osteoclasts. When activated for resorption, these motile cells initially bind to bone, a process well known to be mediated by $\alpha_v\beta_3$ (Davies et al., J. Cell. Biol., 1989 109, 1817-1826; Helfrich et al., J Bone Mineral Res., 1992, 7, 335-343). It is also well known that blockade of $\alpha_v\beta_3$ with antibodies or RGD containing peptides block osteoclast cell adhesion and bone resorption *in vitro* (Horton et al., 15 Exp. Cell Res. 1991, 195, 368-375) and that echistatin, an RGD containing protein, inhibits bone resorption *in vivo* (Fisher et al., Endocrinology, 1993, 132, 1411-1413). More recently, an RGD peptidomimetic has likewise been shown to inhibit osteoclasts *in vitro* and, by i.v. administration *in vivo* prevents osteoporosis (Engleman et al., J. Clin. Invest., 1997, 99, 2284-2292).

20 $\alpha_v\beta_3$ also plays an important role in autoimmune diseases such as psoriasis and rheumatoid arthritis. Peacock, et al., supra.

Numerous patents/applications have claimed various non-peptide $\alpha_v\beta_3$ 25 inhibitors for some or all of the above applications (e.g. EP92307157.5A, EP92307156.7A, WO9708145, WO9532710, WO96/00730, WO9637492, WO9626190, WO9606087, WO97/23451, WO9724119, WO9724122, WO9724124, WO96-US20744961220, EP796855, WO9733887, WO97/34865, WO97/35615, WO97/36859, WO97/35615, WO97/08145, US5668159, WO98/08840, WO98/14192).

-3-

WO9532710 teaches compounds for inhibiting bone resorption. Among the preferred compounds are compounds having a 4-alkyloxy substituted benzoic acid core coupled to an (α -phenylsulfonylamino-3-amino propanoic acid) terminus. None of the exemplary compounds teach a 2-hydroxy substitution of the benzoyl core. The 5 lead compound of WO9532710 exhibited limited bioavailability *in vivo*. (VnR symposium Abstracts, 211th ACS National Meeting, New Orleans, LA, March 24-28 (1996).)

WO9708145 discloses certain meta-guanidine, urea, thiourea and azacyclic amino substituted benzoic acid derivitaves as integrin antagonists.


10 European patent application number EP0320032 broadly claims certain 2-aminoalkoxy-substituted pyridazine derivatives. The compounds disclosed do not comprise an acid functionality.

WO9513262 teaches certain 2-hydroxy-4-heteroarylmethoxy benzamide derivatives are endothelin inhibitors.

15

Detailed Description of the Invention

According to the present invention are provided novel compounds of Formula I:
20 wherein




25

30

-4-

G is

5



R¹ and R² are independently, hydrogen, alkyl of 1 to 6 carbon atoms, mono or bicyclic aralkyl of 6 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

R³ is hydrogen, mono or bicyclic aryl of 6 to 10 carbon atoms, 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O;

R⁴ is hydrogen, NHR⁹, OR⁹, NHCO₂R⁹, NHCONHR⁹, NHCOR⁹ or NHSO₂R⁹; provided that R³ and R⁴ are not both hydrogen;

R⁵ is hydrogen or alkyl of 1 to 6 carbon atoms which may optionally be substituted with a terminal group which serves as a prodrug. For example, the alkyl group may be substituted with an acid, alcohol or amino functionality to form an alkylamino, carboxyalkyl or alkanol group;

R⁶ and R⁷ are independently hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or aralkoxy of 6 to 10 carbon atoms;

-5-

R⁸ and R⁹ are independently hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbons, alkynyl of 2 to 10 carbons, mono or polycycloalkyl of 3-12 carbon atoms, mono or polycycloalkyl-alkyl of 4-12 carbon atoms, mono or bicyclic aryl of 6 to 10-5 carbon atoms, 6 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O, mono or bicyclic aralkyl of 7 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

10 n is an integer from 1 to 4; and m is 0 or 1; or a pharmaceutically acceptable salt thereof.

In some preferred embodiments of the present invention G is 6-15 aminopyridin-2yl, pyridin-2yl, pyrimidyl, tetrahydropyrimidyl, tetrahydropyrimid-4-one, dihydroimidazolyl, amino(imino)-, pyridyl-urea, benzyl-urea, or imidazolidinyl.

In a still more preferred embodiment of the present invention G is 6-amino-pyridin-2-yl, pyridin-2yl, dihydroimidazolyl, 5-amino 1,2,4-triazol-4yl (and/or all tautomers thereof) or tetrahydropyrimidyl, R³ is H, and n is 2 or 3.

20 In some preferred aspects of the invention R9 is methyl, ethyl, n-propyl, i-propyl, allyl, homoallyl, propargyl, pentyl, n-hexyl, octyl, neopentyl, trichloroethyl, n-butyl, i-butyl, butynyl, phenyl, methylphenyl, dimethylphenyl, halophenyl, methoxy-phenyl, acetylphenyl, biphenyl, naphthyl, benzyl, phenethyl, cyclohexyl, cyclohexyl-methyl, trimethylcyclopropyl, phenylcyclopropyl, adamantyl, adamantlylmethyl, 25 cinnamic, pyridyl or dimethylfuranyl.

“Alkyl”, whether used alone or as part of a group such as “alkoxy”, means a branched or straight chain having from 1 to 10 carbon atoms. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl. Lower alkyl refers to alkyl having from 1 to 4 carbon atoms. Alkyl groups may be 30 substituted.

-6-

"Cycloalkyl" as used herein refers to mono or polycyclic alkyl groups of 3-12 carbon atoms. Exemplary cycloalkyl groups include cyclopropyl, cyclohexyl and adamantyl. Cycloalkyl groups may be substituted. One preferred substitution is phenyl.

5 "Aryl" whether used alone or as part of a group such as "aralkyl", means mono or bicyclic aromatic ring having from 6 to 10 carbon atoms. Exemplary aryl groups include phenyl and naphthyl. The aryl may be substituted with one or more substituents. Substituents include halogen, lower alkyl, alkoxy, alkylthio, amino, nitro, cyano, carboxy, carboxyalkyl, alkanoyl, alkylamino, perhaloalkyl, hydroxy, oxy and 10 phenyl. One preferred aryl group is phenyl.

"Heterocycloalkyl" whether used alone or as part of a group such as "heterocycloalkyl-alkyl" means a stable, saturated or unsaturated 5 to 10 membered mono or bicyclic ring having from 1 to 3 heteroatoms selected from N, O and S. Exemplary heterocycloalkyls include pyrazinyl, pyrazolyl, tetrazolyl, furanyl, thienyl, 15 pyridyl, imidazolyl, pyrimidinyl, tetrahydropyrimidinyl, isoxazolyl, thiazolyl, isothiazolyl, quinolinyl, indolyl, isoquinolinyl, oxazolyl and oxadiazolyl. Preferred heteroaryl groups include pyrimidinyl, tetrahydropyrimidinyl, pyridyl, and imidazolyl. Most preferred heteroaryls include pyridin-2yl, and tetrahydropyrimidine. The heteroaryl may also be substituted with one or more substituents. Substituents include 20 halogen, lower alkyl, alkoxy, alkylthio, amino, nitro, cyano, carboxy, carboxyalkyl, alkanoyl, alkylamino, perhaloalkyl, hydroxy, oxy and phenyl. Preferred substituents include amino and oxy. Preferred substituted heterocycloalkyls include 6 aminopyridin-2yl and tetrahydropyrimid-4-one.

25 "Aralkyl" means an aryl-alkyl group in which the aryl and alkyl are as previously described. Exemplary aralkyl groups include benzyl and phenethyl. Use in this context, the alkyl group may include one or more double bonds.

"Heterocycloalkyl-alkyl" means an heterocycloalkyl group in which the heterocycloalkyl and alkyl are as previously described. Use in this context, the alkyl group may include one or more double bonds. Exemplary heterocycloalkyl-alkyls

include pyridylmethyl, pyridylethyl, thienylethyl, thienylmethyl, indolylmethyl, and furylmethyl.

“Alkoxy” means an alkyl-O group in which the alkyl group is as previously described. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, 5 n-butoxy, and t-butoxy.

“Aralkoxy” means an aryl-alkoxy group in which aryl and alkoxy are as previously described.

“Halogen” includes fluorine, chlorine, iodine and bromine.

“Prodrug”, as used herein means a compound which is convertible *in vivo* by 10 metabolic means (e.g. by hydrolysis) to a compound of Formula I.

NMR and IR spectra indicate the 2-hydroxy substitution of Formula I is strongly H-bonded to the adjacent carbonyl, effectively forming a six-membered ring which conformationally restricts the amide residue bearing the carboxy terminus. Thus, the 2- hydroxy substitution of the phenyl core of Formula I plays a significant 15 role in integrin receptor selectivity.

In addition, the 2-hydroxy compounds of the invention are believed to obviate at least two of the three hydrating water molecules which are known to form intermolecular hydrogen bonds with secondary amide functionalities. The energy needed to desolvate water molecules for efficient transport across cell membranes is 20 thus reduced in compounds of the present invention and is believed to contribute to the markedly improved plasma concentrations seen with compounds of the present invention.

Preferred compounds include:

25 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid,

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

30 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,

5 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

10 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

15 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,

25 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,

30 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,

35 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(butoxycarbonyl)amino]propanoic acid},

40 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(isobutoxycarbonyl)amino]propanoic acid},

45 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid,

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

50 (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

55 (2S)-2-{[(hexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

60 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid,

65 (2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-{[(1-adamantylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

5 (2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

10 (2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-15 amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid,

20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxyanilino)carbonyl]amino}propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-25 amino)-2-[(4-methoxyanilino)carbonyl]amino}propanoic acid,

(2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

30 (2S)-2-{[(1,1'-biphenyl)-2-ylamino]carbonyl}amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

35 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(1-naphthylamino)carbonyl]amino}propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-40 amino)-2-[(2-phenylethyl)amino]carbonyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-(isobutyrylamino)propanoic acid,

-10-

(2S)-2-(hexanoylamino)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

5 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-(pentanoylamino)propanoic acid,

(2S)-2-[(3,3-dimethylbutanoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

10 (2S)-2-[(cyclohexylcarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid,

15 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid,

20 (2S)-2-[(2-cyclohexylacetyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(E)-3-phenylprop-2-enoyl]amino]propanoic acid,

25 (2S)-2-[(2-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methylbenzoyl)amino]propanoic acid,

30 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid,

35 (2S)-2-[(4-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid,

40 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid,

(2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

45 (2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

-11-

(2S)-2-[(2-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

5 (2S)-2-[(4-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid

(2S)-2-[(2,3-dimethylbenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-
10 ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-[(3-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-
15 [(phenoxy carbonyl)amino]propanoic acid,

(2S)-2-[(benzyloxy)carbonyl]amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-
ethoxy]benzoyl}amino)propanoic acid,

20 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-
[(isobutoxycarbonyl)amino]propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-
25 methoxyphenoxy)carbonyl]amino}propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid,

(2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-
30 benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-
trichloroethoxy)carbonyl]amino}propanoic acid,

35 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-
40 nitrobenzyl)oxy]carbonyl}amino)propanoic acid,

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid,

45 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-
ynyl oxy)carbonyl]amino}propanoic acid,

-12-

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(4-methylphenoxy)carbonyl]amino } propanoic acid,

5 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-[(methoxycarbonyl)amino]propanoic acid,

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl} amino)propanoic acid,

10 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-[(propoxycarbonyl)amino]propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,

(2S)-2-{ [(allyloxy)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl} amino)propanoic acid,

20 (2S)-2-{ [(but-3-enyloxy)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid,

(2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl} amino)propanoic acid,

25 (2S)-2-{ [(tert-butylamino)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid,

(2S)-2-{ [(butylamino)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid,

30 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(4-methoxyanilino)carbonyl]amino } propanoic acid,

35 (2S)-2-{ [(2-ethylanilino)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid,

(2S)-2-{ [(allylamino)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid,

40 (2S)-2-{ [(2,4-dichloroanilino)carbonyl]amino } -3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid,

45

-13-

(2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-((2-methoxyanilino)carbonyl)amino}propanoic acid,

5 (2S)-2-((2-chloroanilino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

(2S)-2-((2-bromoanilino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

10 (2S)-2-(((1,1'-biphenyl)-2-ylamino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

(2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid,

15 (2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-((4-trifluoromethyl)anilino)carbonyl)amino)propanoic acid,

20 (2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-((4-trifluoromethoxy)anilino)carbonyl)amino)propanoic acid,

(2S)-2-((4-chloroanilino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

25 (2S)-2-((4-fluoroanilino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

(2S)-2-((4-acetylanilino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

30 (2S)-2-((4-ethoxycarbonyl)anilino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

(2S)-2-((cyclohexylamino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

35 (2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-((1-naphthylamino)carbonyl)amino}propanoic acid,

40 (2S)-2-((benzylamino)carbonyl)amino}-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid,

(2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-((2-phenylethyl)amino)carbonyl)amino)propanoic acid,

45

-14-

(2S)-3-((2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl)amino)-2-[(octylamino)carbonyl]amino}propanoic acid,

5 (2S)-2-[(benzyloxy)carbonyl]amino}-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-[(methoxycarbonyl)amino]propanoic acid,

10 (2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-[(ethoxycarbonyl)amino]propanoic acid,

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-[(propoxycarbonyl)amino]propanoic acid,

15 (2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,

20 (2S)-2-[(allyloxy)carbonyl]amino}-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,

(2S)-2-[(but-3-enyloxy)carbonyl]amino}-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,

25 (2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid,

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)-2-[(hexyloxy)carbonyl]amino}propanoic acid,

30 (2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)-2-[(octyloxy)carbonyl]amino}propanoic acid,

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)-2-[(neopentyloxy)carbonyl]amino}propanoic acid,

35 (2S)-2-[(butoxycarbonyl)amino]-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,

40 (2S)-2-[(butylamino)carbonyl]amino}-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,

45 (2S)-2-[(butylamino)carbonyl]amino}-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid,

-15-

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(hexylamino)carbonyl]amino}propanoic acid,

5 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid,

(2S)-2-{[(allylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

10 (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

15 3-({4-[2-(2,5-dihydro-1H-imidazol-4-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-N-{[(1S, 2R)-2-phenylcyclopropyl]amino}carbonyl)alanine,

20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid,

(2S)-2-{[(1,1'-biphenyl)-2-ylamino]carbonyl}amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

25 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-phenylethyl)amino]carbonyl}amino)propanoic acid,

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(isobutyrylamino)propanoic acid,

30 (2S)-2-(butyrylamino)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

35 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(hexanoylamino)propanoic acid,

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pentanoylamino)propanoic acid,

40 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3,3-dimethylbutanoyl)amino]propanoic acid,

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2,2,3,3-tetramethylcyclopropyl)-carbonyl]amino}propanoic acid,

45

(2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

5 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-(pent-4-ynoylamino)propanoic acid,

(2S)-2-[(cyclohexylcarbonyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

10 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(2-phenylacetyl)amino]propanoic acid,

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid,

(2S)-2-[(2-cyclohexylacetyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

20 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid,

(2S)-2-[(2-chlorobenzoyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

25 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(2-methylbenzoyl)amino]propanoic acid,

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid,

(2S)-2-[(4-chlorobenzoyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

30 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(4-methylbenzoyl)amino]propanoic acid,

(2S)-2-[(4-chlorobenzoyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

35 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(4-methylbenzoyl)amino]propanoic acid,

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid,

40 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid,

(2S)-2-[(2-bromobenzoyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

45 (2S)-2-[(2-bromobenzoyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid,

(2S)-2-[(4-bromobenzoyl)amino]-3-{(4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

5 (2S)-3-{(4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,3-dimethylbenzoyl)amino]propanoic acid,

10 (2S)-2-[(3-chlorobenzoyl)amino]-3-{(4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

15 (2S)-2-[(benzyloxy)carbonyl]amino]-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,

20 (2S)-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid,

25 (2S)-2-[(ethoxycarbonyl)amino]-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,

30 (2S)-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,

35 (2S)-2-[(allyloxy)carbonyl]amino]-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,

40 (2S)-2-[(but-3-enyloxy)carbonyl]amino]-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,

45 (2S)-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(octyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(neopentyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{(2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,

(2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid,

5 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}- -amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid,

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(methoxycarbonyl)amino]propanoic acid},

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(ethoxycarbonyl)amino]propanoic acid},

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(propoxycarbonyl)amino]propanoic acid},

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(but-3-enyloxy)carbonyl]amino}propanoic acid,

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(butoxycarbonyl)amino]propanoic acid},

45 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid},

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{[[1,1'-biphenyl]-2-ylmethoxy]carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(([(4-bromobenzyl)oxy]carbonyl)amino)propanoic acid,

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(([(4-fluorobenzyl)oxy]carbonyl)amino)propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(([(2-bromobenzyl)oxy]carbonyl)amino)propanoic acid,

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(4-(trifluoromethyl)benzyl)oxy]carbonyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-toluidinocarbonyl)amino]propanoic acid,

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxyanilino)carbonyl]amino}propanoic acid,

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(2-chloroanilino)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(2-bromoanilino)carbonyl]amino}propanoic acid,

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(1,1'-biphenyl)-2-ylamino]carbonyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-toluidinocarbonyl)amino]propanoic acid,

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(4-(trifluoromethoxy)anilino)carbonyl)amino]propanoic acid,

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(4-chloroanilino)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(4-fluoroanilino)carbonyl]amino}propanoic acid,

40 (2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-([(cyclohexylamino)carbonyl]amino}propanoic acid

-20-

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(1-naphthylamino)carbonyl]amino}propanoic acid,

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(benzylamino)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-phenylethyl)amino]carbonyl]amino}propanoic acid,

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(octylamino)carbonyl]amino}propanoic acid,

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxyanilino)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(anilinocarbonyl)amino]propanoic acid,

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isobutyrylamino)propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(butyrylamino)propanoic acid,

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(hexanoylamino)propanoic acid,

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pentanoylamino)propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3,3-dimethylbutanoyl)amino]propanoic acid,

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid,

(2S)-2-[[2-(1-adamantyl)acetyl]amino]-3-{[4-(2-{[amino(imino)methyl]-amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pent-4-ynoylamino)propanoic acid,

45 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(cyclohexylcarbonyl)amino]propanoic acid,

-21-

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-phenylacetyl)amino]propanoic acid,

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-phenylpropanoyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-cyclohexylacetyl)amino]propanoic acid,

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(*E*)-3-phenylprop-2-enoyl]amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-chlorobenzoyl)amino]propanoic acid,

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methylbenzoyl)amino]propanoic acid,

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxybenzoyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-chlorobenzoyl)amino]propanoic acid,

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methylbenzoyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxybenzoyl)amino]propanoic acid,

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-pyridin-3-ylcarbonyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isonicotinoylamino)propanoic acid,

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid,

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-bromobenzoyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-bromobenzoyl)amino]propanoic acid,

45 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-bromobenzoyl)amino]propanoic acid,

-22-

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,3-dimethylbenzoyl)amino]propanoic acid,

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-chlorobenzoyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(benzoylamino)propanoic acid,

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-ethylbenzoyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-butoxybenzoyl)amino]propanoic acid,

15 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{[(benzyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid,

20 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid,

25 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid,

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid,

30 (2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[(benzylamino)carbonyl]amino}-ethoxy)-2-hydroxybenzoyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(but-3-enyloxy)carbonyl]amino}propanoic acid,

35 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(hexyloxy)carbonyl]amino}propanoic acid,

40 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(octyloxy)carbonyl]amino}propanoic acid,

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(octyloxy)carbonyl]amino}propanoic acid,

45

-23-

- (2S)-3-{[4-(2-{{(benzylamino)carbonyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{(neopentyloxy)carbonyl}amino}propanoic acid,
- 5 (2S)-3-{[4-(2-{{(benzylamino)carbonyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{(2,2,2-trichloroethoxy)carbonyl}amino}propanoic acid,
- (2S)-3-{[4-(2-{{(benzylamino)carbonyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{(butoxycarbonyl)amino}propanoic acid},
- 10 (2S)-3-{[4-(2-{{(benzylamino)carbonyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{(isobutoxycarbonyl)amino}propanoic acid},
- (2S)-2-{{(benzyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino}propanoic acid,
- 15 (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(methoxycarbonyl)amino}propanoic acid},
- (2S)-2-{{(ethoxycarbonyl)amino}-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl}amino}propanoic acid,
- 20 (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(propoxycarbonyl)amino}propanoic acid},
- (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(isopropoxycarbonyl)amino}propanoic acid},
- 25 (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(allyloxy)carbonyl}amino}propanoic acid,
- (2S)-2-{{(but-3-enyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl}amino}propanoic acid,
- 30 (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(prop-2-nyloxy)carbonyl}amino}propanoic acid,
- (2S)-2-{{(hexyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl}amino}propanoic acid,
- 35 (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(octyloxy)carbonyl}amino}propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid,
- 40 (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(octyloxy)carbonyl}amino}propanoic acid,
- (2S)-3-({2-hydroxy-4-[2-{{(pyridin-3-ylmethyl)amino}carbonyl}amino}ethoxy)benzoyl]amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid,

-24-

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,

5 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]-carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,

10 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid,

15 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid,

20 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid,

25 (2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

30 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid,

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

35 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(octyloxy)carbonyl]amino}propanoic acid,

40 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-[(neopentyloxy)carbonyl]amino}propanoic acid,

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid,

-25-

(2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

5 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid,

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methylbenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

10 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methoxybenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(4-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid,

15 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{4-[2-({[(4-(dimethylamino)benzyl]amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino]propanoic acid,

(2S)-3-[{4-[2-({[4-(aminosulfonyl)benzyl]amino]carbonyl}amino)ethoxy}-2-hydroxybenzoyl]amino]-2-{[(benzyloxy)carbonyl]amino}propanoic acid,

20 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{2-hydroxy-4-[2-({[(4-(trifluoromethoxy)benzyl]amino}carbonyl)amino)ethoxy]benzoyl}amino]propanoic acid,

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{4-[2-({[(2-chlorobenzyl)amino]carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino]propanoic acid,

25 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{2-hydroxy-4-[2-({[(2-methylbenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino]propanoic acid,

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{4-[2-({[(2-bromobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino]propanoic acid,

30 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{4-[2-({[(2,4-dichlorobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino]propanoic acid,

(2S)-3-[{4-[2-({[(2-aminobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid,

35 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[{2-hydroxy-4-[2-({[(pyridin-2-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino]propanoic acid,

(2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid,

40 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-2-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid,

45

-26-

(2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino }-propionic acid tert-butyl ester,

5 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(pyrimidin-2-ylamino)-butoxy]-benzoylamino }-propionic acid,

3-{2-Hydroxy-5-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxyl-benzoylamino)-3-phenyl-propionic acid ethyl ester,

10 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino }-propionic acid 2-(2-tert-butoxy-carbonylamino-ethoxy)-ethyl ester,

15 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-butoxy]-benzoylamino }-propionic acid ethyl ester,

(2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino }-propionic acid,

20 3-{2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino }-3-phenyl-propionic acid,

(2S)-2-{Adamantan-1-yloxycarbonylamino)-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid,

25 (2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid ethyl ester,

30 3-{2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy)-benzoylamino)-3-phenyl-propionic acid ethyl ester,

(2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxyl]-benzoylamino }-propionic acid,

35 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino }-propionic acid isopropyl ester,

(2S)-2-tert-Butoxycarbonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino }-propionic acid,

40 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-butoxy]-benzoylamino }-propionic acid,

2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester,

2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid,

5 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride,

2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydrochloride,

10 2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride,

2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride,

15 3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride,

3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid hydrochloride,

20 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester,

3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid,

25 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl-amino]-3-pyridin-3-yl-propanoic acid ethyl ester dihydrochloride,

3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl-amino]-3-pyridin-3-yl-propanoic acid,

3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3-pyridin-3-yl-propanoic acid ethyl ester dihydrochloride,

-28-

3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid,

3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl-amino]-3-phenyl-propanoic acid ethyl ester,

5 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoyl-amino]-3-phenyl-propanoic acid hydrochloride,

3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]-benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride,

10 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]-benzoylamino]-3-phenyl-propanoic acid,

3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino]-3-phenyl-propanoic acid ethyl ester,

3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino]-3-phenyl-propanoic acid,

15 3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]-benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride,

3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]-benzoylamino]-3-phenyl-propanoic,

20 2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydro-chloride,

2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid methyl ester,

2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid,

25 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-methyl-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid, and

2-Amino-3-[2-hydroxy-4-[2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid dihydrochloride, or pharmaceutical salts thereof.

It is understood that the definition of compounds of Formula (I) include —
5 racemates, (racemic mixtures) and individual enantiomers or diastereomers. All asymmetric forms, individual isomers and combinations thereof are within the scope of the present invention.

Optically active isomers may be prepared, for example by resolving the racemic mixtures. The resolution can be carried out by methods known to those skilled in the
10 art such as in the presence of resolving agent, by chiral chromatography, or combinations thereof.

Compounds of Formula I are useful in methods of selectively inhibiting or antagonizing an integrin receptor such as $\alpha_v\beta_3$. More specifically, methods of the present invention include but are not limited to methods of inhibiting cancer (tumor
15 metastasis, tumorigenesis/tumor growth), angiogenesis (as in cancer, diabetic retinopathy, rheumatoid arthritis), restenosis (following balloon angioplasty or stent implantation), inflammation (as in rheumatoid arthritis, psoriasis), bone diseases (osteopenia induced by bone metastases, immobilization and glucocorticoid treatment, periodontal disease, hyperparathyroidism and rheumatoid arthritis), and viral infection
20 by administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.

The compounds of this invention are prepared in accordance with the solid phase combinatorial library synthesis methods or solution phase synthesis methods.

Generally, to prepare the compounds via combinatorial methodology, the
25 starting acylresorcinol ester is condensed with an alkylene chain bearing a terminal primary amino group which is suitably blocked/protected. Methods for this condensation include, but are not limited to selective alkylation of one (the non-H-bonded hydroxyl group) of the resorcinol hydroxy groups, using standard procedures such as the Gabriel synthesis (Angew Chem Int Ed Engl 7, 1968, 919-930 (1968) or
30 Mitsunobu reaction (Synthesis, 1981, 1-28). After conventional deprotection of the N-

-30-

terminus and the acid, the amine 2-2 was protected as fluorenylmethoxy carbamate (Fmoc) 2-6. On the other hand, in the case of G = pyrimidine 2-3, the primary amine 2-2 was activated with trimethylsilyl chloride in the presence of 2-bromopyrimidine in refluxing (anhydrous) 1, 4-dioxane. The carboxylic acid 2-3 was activated as 5 pentafluorophenyl ester 2-5. The carboxylic acid 2-3 was also hydrogenated under catalytic hydrogenation conditions to obtain the tetrahydropyrimidine derivative 2-4.

Orthogonally protected 2,3-diamino propionic acid 1-1 was used for carboxylic acid terminus and was immobilized on polymer support with linkers like but not limited to Wang. The 2-amino group of the 2,3-diaminopropionic acid was Fmoc 10 protected, while the 3- amino group was dde (4,4-dimethyl-2,6-dioxocyclohex-1-ylideneethyl) protected. The 2-amino group was deprotected and further derivatized to 1-4, 1-5, 1-6 and 1-7 using various acylating agents including but not limited to chloroformates, isocyanates, sulfonyl chlorides, carboxylic acids/chlorides. The 3- amino group was deprotected to give 1-8, 1-9, 1-10 and 1-11 and coupled with the 15 resorcinol acid derivatives 2-4, 2-5 or 2-6.


N-terminus derivatives such as dihydroimidazole 5-3, azepine 5-4, guanidine 6-3, and ureas 6-4 were prepared from common primary amine intermediate 4-2.

Schemes 1-6, below, demonstrate the solid phase synthesis practice of this 20 invention as it relates to the examples specified. Detailed synthetic procedures for representative compounds of this invention follow.

Throughout the Examples data for LC (@254 nm) were obtained under the following 25 conditions. HP 1100, 23oC, 10 μ L injected; Column: YMC-ODS-A 4.6 x 50 5 μ ; Gradient A: 0.05% TFA/Water, B: 0.05% TFA/Acetonitrile Time 0 & 1 min: 98%A & 2%B; 7 min: 10%A & 90%B; 8 min: 10%A & 90%B; 8.9 min: 98%A & 2%B; Post time 1 min; Flow rate 2.5 mL min.; Detection: 215 and 254 nm, DAD.

-31-

Scheme 1



2(S)-(Fluorenylmethyloxycarbonyl)amino-3-(4,4-dimethyl-2,6dioxocyclohex-1-ylideneethyl)aminopropionic Acid on Wang Resin (1-2)

5 Wang resin (Wang, S. J. Am. Chem. Soc. 1973, 95, 1328-1333) (Advanced ChemTech 200-400 mesh, 1% crosslinked; loading: 0.92 mmol/g; 5g, 4.6 mmol) was swollen in N,N-dimethylformamide (DMF) (20 mL). A solution of N-a-fmoc-N-b-1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-diaminopropionic acid 1-1 (Fmoc-Dpr(Dde)-OH) (Nova Biochem) (4.513g; 9.2 mmol) in DMF (30mL) was treated with
10 N-hydroxybenzotriazole (HOBT) (1.242g; 9.2 mmol), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) (3.487g; 9.2 mmol) and N,N-diisopropylethylamine (DIEA) (3.2 mL; 18.4 mmol) and added to the resin. The mixture was shaken at room temperature for 8 h. The mixture was filtered and the resin was washed with DMF (3 x 40mL), methanol (MeOH) (3 x 40mL) and
15 dichloromethane (DCM) (3x 40mL). The resin was dried in vacuo to give 6.956g.
Resin Loading: 0.8 mmol/g.

2-Amino-3-(4,4-dimethyl-2,6-dioxocyclohex-1-ylideneethyl)aminopropionic Acid on Wang Resin (1-3)

The resin 1-2 (6.956 g) in DMF was treated with 20% piperidine in DMF (40mL) for
20 10 min and filtered. Another 40mL portion of 20% piperidine in DMF was added to the resin and shaken at room temperature for 20 min. The resin was filtered and washed with DMF (3 x 40mL), MeOH (3 x 40mL) and DCM (3 x 40mL). The resin (1-3) was dried in vacuo.

25 2(S)-(2,2-Dimethyl-propoxycarbonylamino)-3-(4,4-dimethyl-2,6-dioxocyclohex-1-ylideneethyl)amino-propionic acid on Wang Resin (1-4)

The resin 1-3 (925 mg; 0.75 mmol) was swollen in dichloromethane and treated with diisopropylethylamine (969 mg; 1.3 mL; 7.5 mmol) followed by neopentyl

-33-

chloroformate (451.8 mg; 3mmol). The reaction mixture was shaken at room temperature using orbital shaker (Thermolyne RotoMix Type 50800) for 18 h. The mixture were filtered and the resin was washed with dichloromethane (4 x 4 mL), methanol (4 x mL) and dichloromethane (2 x 4 mL). The resins was dried under 5 vacuum. A sample of the was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

A sample of the resin was removed and subjected to cleavage with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The 10 reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. The product was characterized by HPLC: 4.28 min (82% @ 220 nm); MS: 383 (M+H)⁺.

The above reaction conditions were applied for synthesis of urea 1-5 and sulfonamide 15 1-6, using phenyl isocyanate and phenyl sulfonyl chloride, respectively, in the place of neopentyl chloroformate.

A number of chloroformates, isocyanates and sulfonyl chlorides were used in the above reaction.

20 ..

2(S)-benzoylamino-3-(4,4-dimethyl-2,6-dioxocyclohex-1-ylideneethyl)amino-propionic acid on Wang Resin (1-7)

The resin 1-3 (925 mg; 0.75 mmol) was washed with DMF to swell the resin. A solution of benzoic acid (183 mg; 1.5mmole) in DMF was mixed with 25 diisopropylcarbodiimide (192 mg; 0.25 mmole), hydroxybenzotriazole (228 mg; 1.5 mmole) and dimethylaminopyridine (18 mg; 1.5 mmole) and the mixture was added to the resin. The reaction mixture was shaken at room temperature for 16h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol

-34-

(4 x mL) and dichloromethane (4 x 4 mL). The resulting resin **1-7** was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

5

Alternately, carboxylic acids were used in the above reaction in the place of benzoic acid.

3-Amino-2(S)-(2,2-dimethyl-propoxycarbonylamino)-propionic acid on Wang Resin

10 (1-8)


The resin **1-4** was shaken with a solution of 2% hydrazine in dimethylformamide (3mL) for 5 min. at room temperature. The reaction mixture was filtered and an additional 3 mL of a solution of 2% hydrazine in dimethylformamide was added and the reaction mixture was shaken at room temperature for 5 min. The mixture was 15 filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test for the presence of free amine (resin turns blue).

A sample of the resin was removed and subjected to cleavage with dichloromethane 20 (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. The product was characterized by HPLC: 4.686 min (78% @ 220 nm); MS m/z 219 (M+H)⁺.

25 Resin bound compounds **1-5**, **1-6** and **1-7** were subjected to similar deprotection condition to afford the free amines **1-9**, **1-10** and **1-11** respectively.

-35-

Scheme 2



5

Methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate (2-1)

Methyl 2, 4-dihydroxy benzoate (14.5g, Aldrich), 2-(N-t-butoxycarbonyl)ethanol (13.9g, Aldrich) and triphenyl phosphine (22.6g, Aldrich) were combined in 350 mL of 10 THF and cooled in ice under N₂ atmosphere. Diethyl diazodicarboxylate (DEAD,

-36-

15g, Aldrich) was added, the ice bath removed and the reaction mixture allowed to stir at ambient temperature for 15h. The solvent was removed on a rotary evaporator and the residue chromatographed on silica gel (300g, Merck silica 60), elution with CH₂Cl₂ to give 18g of methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate, —
5 as a viscous oil. NMR (300 MHz, CDCl₃) δ 11.0 (s, 1 H), 9.5 (d, J = 8Hz, 1H), 6.4 (m, 2H), 5.0 (broad, 1H), 4.0 (t, J = 5Hz, 2H), 3.91 (s, 3H), 3.54 (m, 2H), 1.45 (s, 9H), MS (+ESI) m/z 334 (M+Na)⁺.

4-(2-Aminoethoxy)-2-hydroxybenzoic acid, hydrochloride (2-2)

10

Ester 2-1 (7.2g) was treated with 5eq. KOH (dissolved in minimum amount of water and equal volume of 1, 4-dioxane) at room temperature until TLC indicated complete absence of starting material (3-12h). The reaction mixture was acidified (pH = 6) with the addition of 1N HCl solution and extracted with ethyl acetate. The extract was
15 washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated on the rotary evaporator. The crude product (5.34g) was recrystallized from ether, then dissolved in 1, 4-dioxane and treated with an excess of anhydrous HCl (4M in dioxane, Aldrich). The mixture was allowed to stand at ambient temperature for 24h. Volatile materials were removed in vacuo on the rotary
20 evaporator to give 2-2 as a hydroscopic off-white solid. NMR (400 MHz, DMSO-d6) δ 13.6 (broad, 1H), 11.6 (broad, 1H), 8.3 (broad, 3H), 7.7 (d, J = 9 Hz, 2H), 6.53 (m, 2H), 4.23 (t, J = 5Hz, 2H), 3.2 (s, broad, 2H).

2-Hydroxy-4-[2-(pyrimidine-2ylamino)ethoxy]benzoic acid (2-3)

25

A mixture of compound 2-2 (20g), diisopropylethylamine (DIPEA, 74 mL), trimethylsilylchloride (TMSCl, 21.6 mL) and 2-bromopyrimidine (Lancaster, 13.5g) were combined in 350 mL 1, 4-dioxane at room temperature, then brought to reflux under N₂ atmosphere. After 2 days, an additional 12 mL trimethylsilyl chloride was
30 added, and the mixture continued at reflux for an additional 2 days (until TLC showed

-37-

no starting material remained). The reaction mixture was cooled to ambient temperature, concentrated to dryness in vacuo on a rotary evaporator and the residue suspended in water. The heterogeneous mixture was refluxed briefly, allowed to cool to room temperature, the product collected on a vacuum filter and air dried to give

5 15.3g of 2-3, as a tan powder. NMR (400 MHz, DMSO-d₆) δ 12 (very broad, 2H) 8.3 (d, J = 5 Hz, 2H) 7.7 (d, J = 9Hz, 1H), 7.28 (t, J = 6Hz, 1H), 6.57 (t, J = 5Hz, 1H), 6.49 (m, 2H), 4.13 (t, J = 6Hz, 2H), 3.62 (q, 2H); MS (+ESI) m/z 276 (M+H)⁺; IR (KBr) ν (cm⁻¹) 3275, 3000, 1660, 1625.

10 2-Hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2ylamino) ethoxy]-benzoic acid (2-4).

Compound 2-3 (2g) was combined with 10% Pd/C (0.5g), acetic acid (100 mL) and concentrated hydrochloric acid (0.7 mL). The mixture was stirred at room temperature under an atmosphere of H₂ (balloon) for 2 days. Celite was added and the

15 mixture stirred for 0.5h, then filtered through a pad of celite with the aid of isopropanol. Volatile materials were removed on the rotary evaporator and the residue warmed with heptane (~0.5h, 100°C) followed by concentration in vacuo to give 2-4 as a tan foam. NMR (400 MHz, DMSO-d₆) δ 12.9 (broad, 2H), 8.25 (s, broad, 2H), 7.85 (t, J = 6Hz, 1H), 7.66 (d, J = 9 Hz, 1H), 6.48 - 6.41 (m, 2H), 4.07 (t, J = 5Hz, 2H), 3.56 - 3.50 (m, 2H), 3.22 (m, 2H, overlapping with H₂O peak), 1.79 (m, 2H); IR (KBr) n (cm⁻¹) 3450 (broad); MS (+ESI) m/z 280 (M + H)⁺.

20 2,3,4,5,6-Pentafluorophenyl 2-hydroxy-4-[2-(pyrimidine-2-ylamino)ethoxy]-benzoate (2-5)

25 Acid 2-3 (1.18g; 4.3 mmol) in dioxane (40 mL) was treated with DIEA (1.5 mL; 8.6 mmol) and cooled to 0°C. Pentafluorophenol (3.16g; 17.2 mmol) was added followed by dicyclohexyl carbodiimide. The reaction mixture was allowed to warm to room temperature and stirred for additional 16 h. The solid precipitated was filtered off and

30 the mother liquor was concentrated to dryness and the residue was purified using silica

-38-

column chromatography, eluted with 50% ethyl acetate in hexane to give 1.01 g of 2-5 as a white solid. NMR (300 MHz, CDCl₃) δ 10.0 (s, 1H), 8.3 (d, J = 5 Hz, 2H) 8.0 (d, J = 9Hz, 1H), 6.57 (t, J = 5Hz, 1H), 6.49 (m, 2H), 5.5 (t, J = 3Hz, 1H), 4.2 (t, J = 6Hz, 2H), 3.9 (q, 2H).


5

4-[*(2-fluorenylmethyloxycarbonylamino)ethoxy*]-2-hydroxybenzoic acid (2-6)

The Amino acid 2-2 (1.864g; 8 mmol) was dissolved in 1:1 acetone - water (50 mL) containing sodium carbonate (1.696g; 16 mmol). To the solution was added Fmoc-Osu (2.696 g; 8 mmol) in acetone (25 mL) dropwise at room temperature. The solution was stirred at room temperature for 18 h. The reaction mixture was concentrated and the residue was dissolved in water and extracted with ether (2 x 50 mL). The aqueous layer was cooled in an ice bath and acidified with 6N HCl to pH 3. The solid obtained was filtered and washed with water and dried under vacuo (3.22g).
10 NMR (300 MHz, DMSO-d₆) δ 7.9 (d, 2H), 7.65-7.75 (m, 2H), 7.55 (t, 2H), 7.4 (t, 2H), 7.3 (t, 2H), 6.5 (m, 2H), 4.35 (d, 2H), 4.25 (t, 1H), 4.05 (t, 2H), 3.4 (t, 2H).
15

-39-

Scheme 3



Example 1 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid (3-2)

5

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid on Wang Resin (3-1)

The resin 1-8 (100mg) was washed with DMF to swell the resin. A solution of
10 2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoic acid 2-4 (70 mg; 0.25mmole) in DMF was mixed with diisopropylcarbodiimide (32 mg; 0.25 mmole), hydroxybenzotriazole (38mg; 0.25 mmole) and dimethylaminopyridine (3 mg; 0.025 mmole) and the mixture was added to the resin. The reaction mixture was shaken at room temperature for 16h. The mixture was filtered and the resin was
15 washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resulting resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

20 The resin 3-1 was treated with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 3-2 was purified via preparative HPLC. NMR (400MHz, MeOH-d4) δ 7.7 (d, J = 7 Hz, 1H), 6.5 (m, 2H), 4.45 (q, 1H), 4.1 (t, 2H), 3.8 - 3.65 (m, 4H), 3.55 (t, 2H), 3.35 (t, 4H), 2.0 (m, 2H), 0.9 (s, 9H).

HR-MS FAB m/z for C₂₂H₃₃N₅O₇ calcd. 480.2458 (M⁺+1), obsd. 480.2431.

-41-

The following compounds were synthesized as described in the above Scheme 3 (Path A), using various resin bound carbamates in the place of (1-8). These compounds were characterized using LC and MS as shown in Table 1.

5 Example 2

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid.

10 Example 3

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

15 Example 4

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid.

20 Example 5

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

25 Example 6

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

30 Example 7

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

35 Example 8

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

40 Example 9

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

-42-

Example 10

(2S)-3-{(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

5

Example 11

(2S)-3-{(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-[(butoxycarbonyl)amino]propanoic acid.

10

Example 12

(2S)-3-{(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

15

Example 13

(2S)-3-{(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid.

20


Example 14

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino}propanoic acid.

25

-43-

Table 1



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
2	Methyl	2.92 min	424	8	n-Hexyl	4.12 min	494
3	Ethyl	3.09 min	438	9	n-Octyl	4.62 min	522
4	n-Propyl	3.30 min	452	1	(CH ₃) ₃ CCH ₂	3.77 min	480
5	i-Propyl	3.28 min	452	10	(CCl ₃) ₃ CCH ₂	3.81 min	542
6	Allyl	3.21 min	450	11	n-Butyl	3.60 min	466
7	Homoallyl	3.46 min	463	12	i-Butyl	3.58 min	466
13	Propargyl	3.18 min	448	14	Benzyl	3.74 min	500

5 The following compounds were synthesized as described in the above Scheme 3, (Path A) using various resin linked ureas 1-9 in the place of carbamate (1-8). These compounds were characterized using LC and MS as shown in Table 2.

Example 15

(2S)-2-{[(butylamino)carbonyl]amino}-3-((2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

10

Example 16

(2S)-2-{[(hexylamino)carbonyl]amino}-3-((2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

15

Example 17

(2S)-3-((2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid.

Example 18

20 (2S)-2-{[(allylamino)carbonyl]amino}-3-((2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

-44-

Example 19

(2S)-2-{[(1-adamantylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 **Example 20**

(2S)-2-{[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

10 **Example 21**

(2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

15 **Example 22**

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

20 **Example 23**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(4-toluidinocarbonyl)amino]propanoic acid.

25 **Example 24**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2-toluidinocarbonyl)amino]propanoic acid.

30 **Example 25**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid.

35 **Example 26**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid.

40 **Example 27**

(2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

45 **Example 28**

(2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

40 **Example 29**

(2S)-2-{[(1,1'-biphenyl)-2-ylamino]carbonyl}amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

-45-

Example 30

(2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.


5 **Example 31**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid.

10 **Example 32**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2-phenylethyl)amino]carbonyl}amino)propanoic acid.

Table 2



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
15		3.30 min	465	24		3.45 min	499
16		3.77 min	493	25		3.50 min	515
17		4.31 min	521	26		3.39 min	515
18		3.02 min	449	27		3.60 min	521
19		4.00 min	543	28		3.60 min	565
20		3.42 min	485	29		3.95 min	561
21		3.45 min	491	30		3.79 min	521
22		3.43 min	499	31		3.67 min	535

-46-

23		3.62 min	499	32		3.56 min	513
----	--	----------	-----	----	--	----------	-----

The following compounds were synthesized as described in the above Scheme 3, (Path A) using various resin linked amides 1-11 in the place of carbamate (1-8). These compounds were characterized using LC and MS as shown in Table 3.

5 Example 33

(2S)-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)-amino)-2-(isobutyrylamino)propanoic acid.

10 Example 34

(2S)-2-(hexanoylamino)-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

15 Example 35

(2S)-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)-amino)-2-(pentanoylamino)propanoic acid.

20 Example 36

(2S)-2-[(3,3-dimethylbutanoyl)amino]-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

25 Example 37

(2S)-2-[(cyclohexylcarbonyl)amino]-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

30 Example 38

(2S)-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)-amino)-2-[(2-phenylacetyl)amino]propanoic acid.

35 Example 39

(2S)-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid.

40 Example 40

(2S)-2-[(2-cyclohexylacetyl)amino]-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)amino)propanoic acid.

45 Example 41

(2S)-3-(2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl)-amino)-2-[(E)-3-phenylprop-2-enoyl]amino}propanoic acid.

-47-

Example 42

(2S)-2-[(2-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5

Example 43

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-methylbenzoyl)amino]propanoic acid.

10 **Example 44**

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid.

Example 45

15 (2S)-2-[(4-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 46

20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid.

Example 47

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid.

25

Example 48

(2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

30 **Example 49**

(2S)-2-[(2-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 50

35 (2S)-2-[(4-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 51

40 (2S)-2-[(2,3-dimethylbenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.


Example 52

(2S)-2-[(3-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

45

-48-

Table 3



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
33		3.03 min	436	43		3.42 min	484
34		3.46 min	464	44		3.48 min	500
35		3.24 min	450	45		3.70 min	504
36		3.37 min	464	46		3.57 min	484
37		3.49 min	476	47		3.44 min	500
38		3.35 min	484	48		3.59 min	488
39		3.54 min	498	49		3.39 min	548
40		3.62 min	490	50		3.76 min	548
41		3.66 min	496	51		3.58 min	498
42		3.36 min	504	52		3.70 min	504

-49-

**Example 53 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}-
amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (3-4)
(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-
{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (3-3)**

5

The resin 1-8 (100mg) was washed with DMF to swell the resin and was treated with a solution of 2,3,4,5,6-pentafluorophenyl 2-hydroxy-4-[2-(pyrimidine-2-ylamino)ethoxy]-benzoate 2-5 (110 mg; 0.25mmole) in DMF. The reaction mixture was shaken at room temperature for 16h. The mixture was filtered and the resin was 10 washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resulting resin 3-3 was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

15 The resin 3-3 was treated with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 3-4 was purified via preparative HPLC. 3.907 min (78% @ 220 nm); MS m/z 476 (M+H)⁺.

20

The following compounds were synthesized as described in the above Scheme 3 (Path B), using various resin bound carbamates in the place of (1-8). These compounds were characterized using LC and MS as shown in Table 4.

Example 54

25 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-
{(phenoxy carbonyl)amino}propanoic acid.

Example 55

30 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 56

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-
{(isobutoxycarbonyl)amino}propanoic acid.

-50-

Example 57

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(4-methoxyphenoxy)carbonyl]amino }propanoic acid.

5 **Example 58**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(octyloxy)carbonyl]amino }propanoic acid.

10 **Example 59**

10 (2S)-2-{(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid.

15 **Example 60**

15 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino }propanoic acid.

20 **Example 61**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(4-nitrobenzyl)oxy]carbonyl}amino)propanoic acid.

20

Example 62

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid.

25

Example 63

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(prop-2-ynyl)carbonyl]amino }propanoic acid.

30

Example 64

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(4-methylphenoxy)carbonyl]amino }propanoic acid.

35

Example 65

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(methoxycarbonyl)amino]propanoic acid.

40

Example 66

(2S)-2-{(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)propanoic acid.

Example 67

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl} amino)-2-{[(propoxycarbonyl)amino]propanoic acid.

45

-51-

Example 68

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.


5 **Example 69**

(2S)-2-{{(allyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 70

10 (2S)-2-{{(but-3-enyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Table 4



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
54	Phenyl	3.77 min	481	62	n-Hexyl	4.26 min	490
55	Benzyl	3.88 min	495	63	Propargyl	3.30 min	444
56	i-Butyl	3.73 min	461	64	p-Me-Phenyl	3.94 v	496
57	p-OMe-phenyl	3.75 min	511	65	Methyl	3.06 v	420
58	Octyl	4.79 min	517	66	Ethyl	3.26 min	434
59	n-Butyl	3.77 min	462	67	n-Propyl	3.48 v	448
60	CCl ₃ CH ₂	3.94 min	538	68	i-Propyl	3.46 v	448
53	neopentyl	3.90 min	476	69	Allyl	3.40 min	446
61	p-NO ₂ -Benzyl	3.80 min	541	70	Homoallyl	3.58 min	460

15

The following compounds were synthesized as described in the above Scheme 3 (Path B), using various resin bound ureas 1-9 in the place of (1-8). These compounds were characterized using LC and MS as shown in Table 5.

-52-

Example 71

(2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid

5 **Example 72**

(2S)-2-{{(tert-butylamino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

10 **Example 73**

(2S)-2-{{(butylamino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

15 **Example 74**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(4-methoxyanilino)carbonyl}amino}propanoic acid

20 **Example 75**

(2S)-2-{{(2-ethylanilino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

25 **Example 76**

(2S)-2-{{(allylamino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid

30 **Example 77**

(2S)-2-{{(2,4-dichloroanilino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

35 **Example 78**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid.

40 **Example 79**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(2-methoxyanilino)carbonyl}amino}propanoic acid.

45 **Example 80**

(2S)-2-{{(2-chloroanilino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

50 **Example 81**

(2S)-2-{{(2-bromoanilino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

-53-

Example 82

(2S)-2-{[(1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 **Example 83**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid.

10 **Example 84**

10 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-([4-(trifluoromethyl)anilino]carbonyl)amino)propanoic acid.

15 **Example 85**

15 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-([4-(trifluoromethoxy)anilino]carbonyl)amino)propanoic acid.

20 **Example 86**

20 (2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

25 **Example 87**

25 (2S)-2-{[(4-fluoroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

30 **Example 88**

30 (2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

35 **Example 89**

35 (2S)-2-([4-(ethoxycarbonyl)anilino]carbonyl)amino)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

40 **Example 90**

40 (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

45 **Example 91**

45 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(1-naphthylamino)carbonyl]amino)propanoic acid.

50 **Example 92**

50 (2S)-2-{[(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid.

-54-

Example 93


(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid

5 **Example 94**

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(octylamino)carbonyl}amino}propanoic acid

Table 5

10




Ex.	R ₉	LC @ 254 nm	(M+H) ⁺	Ex.	R ₉	LC @ 254 nm	(M+H) ⁺
71		3.70 min	480	83		3.79 min	495
72		3.45 min	460	84		4.22 min	549
73		3.50 min	460	85		4.27 min	565
74		3.56 min	510	86		3.96 min	515
75		3.81 min	508	87		3.68 min	499
76		3.13 min	444	88		3.50 min	523
77		4.19 min	549	89		3.92 min	553
78		3.63 min	495	90		3.66 min	487
79		3.68 min	511	91		3.86 min	487

-55-

80		3.78 min	515	92		3.55 min	495
81		3.80 min	559	93		3.70 min	509
82		4.13 min	557	94		4.56 min	517

Scheme 4



5 2(S)-(2,2-dimethyl-propoxycarbonylamino)-3-{[2-Hydroxy-4-(2-fluorenylmethoxy-carbonylamino)ethoxy]benzoylamino}-propionic acid on Wang Resin (4-1)

The resin 1-8 was washed with DMF to swell the resin. A solution of 4-[(2-fluorenylmethoxy carbonylamino)ethoxy]-2-hydroxybenzoic acid (2-6) (628.5 mg; 1.5 mmole) in DMF was mixed with diisopropylcarbodiimide (189 mg; 1.5 mmole), hydroxybenzotriazole (202.5 mg; 1.5 mmole) and dimethylaminopyridine (18.33 mg; 0.15 mmole) and the mixture was added to the resin. The reaction mixture was shaken

-56-

at room temperature for 16h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

2(S)-(2,2-dimethyl-propoxycarbonylamino)-3-[2-Hydroxy-4-(2-aminoethoxy)benzoyl-amino]-propionic acid on Wang Resin (4-2)

The resin 4-1 was shaken with a solution of 20% piperidine in DMF (5mL) for 10 min and filtered. Another 5mL portion of 20% piperidine in DMF was added and shaken at room temperature for 20 min. The resin was filtered and washed with DMF (3 x 40mL), MeOH (3 x 40mL) and DCM (3 x 40mL). The resin were dried under vacuum.


A sample of the resin was removed and subjected to cleavage with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. The product was characterized by HPLC: 3.35 min (70% @ 220 nm); MS m/z 398 (M+H)⁺.

20

25

-57-

Scheme 5



Example 95 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (**5-2**)

5 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (**5-1**)

The resin **4.2** (100mg; 0.1mmole) was swollen in DMF. To the resin was added a solution of 2-(3,5-dimethylpyrazolyl)-4,5-dihydroimidazole hydrobromide (123 mg; 0.5 mmole) in DMF (1.5 mL) followed by diisopropylamine (0.15 mL; 1 mmole). The reaction vessel was shaken at 60 °C for 18h. The mixture was filtered and the resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x 4 mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

-58-

The resin 5-1 was cleaved by treatment with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 5-2 was purified
5 via preparative HPLC. NMR (300MHz, MeOH-d4) δ 7.7 (d, J = 7 Hz, 1H), 6.5 (m, 2H), 4.5 (q, 1H), 4.2 (t, 2H), 3.85 (m, 1H), 3.75-3.8 (m, 7H), 3.5 (t, 2H), 0.9 (s, 9H).
HR-MS FAB m/z for C₂₁H₃₁N₅O₇ calcd. 466.2302 (M⁺+1), obsd. 466.2289.

The following compounds were synthesized as described in the above Scheme 5 (Path
10 A), using various resin bound carbamates in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 6.

Example 96

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

15

Example 97

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid.

20

Example 98

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(ethoxycarbonyl)amino]propanoic acid.

25

Example 99

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid.

30

Example 100

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

35

Example 101

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 102

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

-59-

Example 103

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid.

5 **Example 104**

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(hexyloxy)carbonyl]amino}propanoic acid.

10 **Example 105**

10 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(octyloxy)carbonyl]amino}propanoic acid.

15 **Example 106**


(2S)-2-[(butoxycarbonyl)amino]-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-

15 ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid.

20 **Example 107**

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

Table 6



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
97	Methyl	2.82 min	410	104	n-Hexyl	3.97 min	480
98	Ethyl	2.99 min	424	105	n-Octyl	4.49 min	508
99	n-Propyl	3.21 min	438	95	(CH3)3CCH2	3.63 min	466
100	i-Propyl	3.17 min	438	106	n-Butyl	3.46 min	452
101	Allyl	3.13 min	436	107	i-Butyl	3.44 min	452
102	Homoallyl	3.31 min	450	96	Benzyl	3.60 min	486
103	Propargyl	3.01 min	434				

25 The following compounds were synthesized as described in the above Scheme 5 (Path A), using various resin bound ureas in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 7.

-60-

Example 108

(2S)-2-{[(butylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

5 **Example 109**

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(hexylamino)carbonyl]amino}propanoic acid.

10 **Example 110**

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid.

15 **Example 111**

(2S)-2-{[(allylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

20 **Example 112**

(2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

25 **Example 113**

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

30 **Example 114**

3-({4-[2-(2,5-dihydro-1H-imidazol-4-ylamino)ethoxy]-2-hydroxybenzoyl}amino-N-(({{(1S,2R)-phenylcyclopropyl]amino)carbonyl}alanine.

35 **Example 115**

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid.

40 **Example 116**

(2S)-2-{[{[1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

45


Example 117

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(2-phenylethyl)amino]carbonyl}amino)propanoic acid.

50

-61-

Table 7



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
108		3.20 min	451	113		3.26 min	485
109		3.69 min	479	114		3.57 min	511
110		4.24 min	507	115		3.42 min	501
111		2.84 min	435	116		3.89 min	547
112		3.37 min	477	117		3.47 min	499

The following compounds were synthesized as described in the above Scheme 5 (Path 5 A), using various resin bound amides in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 8.

Example 118

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-(isobutyrylamino)propanoic acid.

10

Example 119

(2S)-2-(butyrylamino)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)amino)propanoic acid.

15 **Example 120**

(2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-(hexanoylamino)propanoic acid.

Example 121

20 (2S)-3-((4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl)-amino)-2-(pentanoylamino)propanoic acid.

-62-

Example 122

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3,3-dimethylbutanoyl)amino]propanoic acid.

5 Example 123

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid.

Example 124

10 (2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 125

15 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pent-4-ynoylamino)propanoic acid.

Example 126

20 (2S)-2-[(cyclohexylcarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 127

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid.

25 Example 128

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid.

Example 129

30 (2S)-2-[(2-cyclohexylacetyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

Example 130

35 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(E)-3-phenylprop-2-enoyl]amino}propanoic acid.

Example 131

(2S)-2-[(2-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid.

40

Example 132

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2-methylbenzoyl)amino]propanoic acid.

-63-

Example 133

(2S)-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)ethoxy]-2\text{-hydroxybenzoyl}\}$ -amino)-2-[(2-methoxybenzoyl)amino]propanoic acid.

5 **Example 134**

(2S)-2-[(4-chlorobenzoyl)amino]-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)-ethoxy]-2\text{-hydroxybenzoyl}\}$ amino)propanoic acid.

10 **Example 135**

10 (2S)-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)ethoxy]-2\text{-hydroxybenzoyl}\}$ -amino)-2-[(4-methylbenzoyl)amino]propanoic acid.

15 **Example 136**

15 (2S)-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)ethoxy]-2\text{-hydroxybenzoyl}\}$ -amino)-2-[(4-methoxybenzoyl)amino]propanoic acid.

20 **Example 137**

20 (2S)-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)ethoxy]-2\text{-hydroxybenzoyl}\}$ -amino)-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid.

25 **Example 138**

25 (2S)-2-[(2-bromobenzoyl)amino]-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)-ethoxy]-2\text{-hydroxybenzoyl}\}$ amino)propanoic acid.

30 **Example 139**

30 (2S)-2-[(4-bromobenzoyl)amino]-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)ethoxy]-2\text{-hydroxybenzoyl}\}$ amino)propanoic acid.

35 **Example 140**


35 (2S)-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)ethoxy]-2\text{-hydroxybenzoyl}\}$ -amino)-2-[(2,3-dimethylbenzoyl)amino]propanoic acid.

Example 141

(2S)-2-[(3-chlorobenzoyl)amino]-3-($\{4-[2-(4,5\text{-dihydro-}1\text{H-imidazol-}2\text{-ylamino)-ethoxy]-2\text{-hydroxybenzoyl}\}$ amino)propanoic acid.

-64-

Table 8



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
118		2.90 min	422 (M+H)	130		3.57 min	482 (M+H)
119		2.90 min	422 (M+H)	131		3.24 min	490 (M+H)
120		3.34 min	450 (M+H)	132		3.30 min	470 (M+H)
121		3.10 min	436 (M+H)	133		3.38 min	486 (M+H)
122		3.26 min	450 (M+H)	134		3.59 min	490 (M+H)
123		3.71 min	476 (M+H)	135		3.46 min	470 (M+H)
124		3.90 min	528 (M+H)	136		3.34 min	486 (M+H)
125		2.86 min	432 (M+H)	137		3.45 min	474 (M+H)
126		3.36 min	462 (M+H)	138		3.16 min	534 (M+H)
127		3.22 min	470 (M+H)	139		3.28 min	534 (M+H)
128		3.42 min	484 (M+H)	140		3.65 min	484 (M+H)
129		3.50 min	476 (M+H)	141		3.56 min	490 (M+H)

-65-

Example 142 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid (5-4)

5

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid on Wang Resin (5-3)

The resin 4-2 (100 mg; 0.1mmole) was swollen in dioxane and treated with a solution of 1-aza-2-methoxy-1-cycloheptene (127 mg; 1 mmole) in dioxane (1.5 mL).

10 The reaction mixture was shaken at room temperature for 18h. The mixture was filtered and the resin was washed with dioxane (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence of free amine (resin turned blue) the coupling described above was repeated.

15

The resin 5-3 was cleaved by treatment with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 5-4 was purified via preparative HPLC. NMR (300MHz, DMSO-d6) δ 12.8 (s, 1H), 9.55 (t, 1H), 9.25 (t, 1H), 8.8 (t, 1H), 7.8 (d, J = 9 Hz, 1H), 7.7 (d, J = 8 Hz, 1H), 7.3 (m, 5H), 6.5 (m, 2H), 5.0 (s, 2H), 4.3 (q, 1H), 4.2 (t, 2H), 3.8 (m, 3H), 3.6 (m, 1H), 3.5 (m, 2H), 2.7 (m, 2H), 1.7 (m, 2H), 1.6 (m, 4H).

25 The following compounds were synthesized as described in the above Scheme 5 (Path B), using various resin bound carbamates in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 9.

-66-

Example 143

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

5 Example 144

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid.

Example 145

10 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 146

15 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.

Example 147

20 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

Example 148

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

25 Example 149

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 150

30 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid.

Example 151

35 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid.

Example 152

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

40

Example 153

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

-67-

Example 154

(2S)-2-[(butoxycarbonyl)amino]-3-((2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl)amino)propanoic acid.


5

Example 155

(2S)-3-((2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl)amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

10


Table 9



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
144	Methyl	3.08 min	437	151	n-Hexyl	3.19 min	507
145	Ethyl	3.25 min	451	152	n-Octyl	4.67 min	535
146	n-Propyl	3.46 min	465	142	(CH ₃) ₃ CCH ₂	3.85 min	493
147	i-Propyl	3.38 min	465	153	(CCl ₃) ₃ CCH ₂	3.89 min	553
148	Allyl	3.37 min	463	154	n-Butyl	3.70 min	479
149	Homoallyl	3.55 min	477	155	i-Butyl	3.67 min	479
150	Propargyl	3.27 min	461	143	Benzyl	3.83 min	513

-68-

Scheme 6



Example 156 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxy-
5 benzoyl]amino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (6-2)

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (6-1)

The resin 4-2 (100 mg; 0.1mmole) was swollen in DMF and treated with a solution of
10 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (145 mg; (0.5 mmole) in
DMF (1.5 mL) followed by diisopropylamine (0.15 mL; 1 mmole). The reaction
mixture was shaken at room temperature for 18h. The mixture was filtered and the
resin was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and
dichloromethane (4 x 4 mL). The resin was dried under vacuum. A sample of the resin
15 was removed and subjected to Kaiser Ninhydrin test. If the test showed the presence
of free amine (resin turned blue) the coupling described above was repeated.

The resin 6-1 was cleaved by treatment with dichloromethane (0.5 mL) and trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 6-2 was purified via preparative HPLC. NMR (300MHz, MeOH-d4) δ 7.7 (d, J = 7 Hz, 1H), 6.5 (m, 2H), 4.5 (q, 1H), 4.2 (m, 2H), 3.85 (m, 1H), 3.8 (m, 2H), 3.75 (m, 1H), 3.7 (m, 2H), 0.9 (s, 9H).

HR-MS FAB m/z for C₁₉H₂₉N₅O₇ calcd. 440.2145 (M⁺+1), obsd. 440.2154.

10

The following compounds were synthesized as described in the above Scheme 6 (Path A), using various resin bound carbamates in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 10.

15 Example 157

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(benzyloxy)carbonyl]amino}propanoic acid.

Example 158

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid.

Example 159

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid.

Example 160

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid.

30

Example 161

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid.

35 Example 162

(2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

-70-

Example 163

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(but-3-enyloxy)carbonyl]amino}propanoic acid.

5 Example 164

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid.

10 Example 165

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

15 Example 166

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(hexyloxy)carbonyl]amino}propanoic acid.

20 Example 167

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid.

25 Example 168

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[[([1,1'-biphenyl]-2-ylmethoxy)carbonyl]amino}propanoic acid.

30 Example 169

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-((4-bromobenzyl)oxy)carbonyl]amino}propanoic acid.

Example 170

35 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-((4-fluorobenzyl)oxy)carbonyl]amino}propanoic acid.

Example 171


(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-((2-bromobenzyl)oxy)carbonyl]amino}propanoic acid.

Example 172

40 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(((4-(trifluoromethyl)benzyl)oxy)carbonyl)amino}propanoic acid.

-71-

Table 10



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
158	Methyl	2.75 min	384	165	(CCl ₃) ₃ CCH ₂	3.60 min	502
159	Ethyl	2.93 min	397	164	n-Butyl	3.39 min	426
160	n-Propyl	3.15 min	412	157	Benzyl	3.53 min	460
161	i-Propyl	3.11 min	412	168		4.20 min	536
162	Allyl	3.05 min	410	169		3.85 min	539
163	Homoallyl	3.25 min	424	170		3.60 min	478
167	Propargyl	2.95 min	408	171		3.81 min	539
166	n-Hexyl	3.91 min	4454	172		3.97 min	528
156	(CH ₃) ₃ CCH ₂	3.57 min	440				

5 The following compounds were synthesized as described in the above Scheme 6 (Path A), using various resin bound ureas in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 11.

10 Example 173
 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-toluidinocarbonyl)amino]propanoic acid.

Example 174
 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxyanilino)carbonyl]amino]propanoic acid.

-72-

Example 175

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-chloroanilino)carbonyl]amino } propanoic acid.

Example 176

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-bromoanilino)carbonyl]amino } propanoic acid.

Example 177

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(1,1'-biphenyl]-2-ylamino)carbonyl]amino } propanoic acid.

Example 178

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[
[(4-toluidinocarbonyl)amino]propanoic acid.

Example 179

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-trifluoromethoxy)anilino]carbonyl}amino } propanoic acid.

Example 180

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-chloroanilino)carbonyl]amino } propanoic acid.

Example 181

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-fluoroanilino)carbonyl]amino } propanoic acid

Example 182

(2S)-2-{[(4-acetylanilino)carbonyl]amino }-3-{[4-(2-{[amino(imino)methyl]-
amino}ethoxy)-2-hydroxybenzoyl]amino } propanoic acid.

Example 183

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(cyclohexylamino)carbonyl]amino } propanoic acid.

Example 184

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(1-naphthylamino)carbonyl]amino } propanoic acid.

Example 185

45 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(benzylamino)carbonyl]amino } propanoic acid.

-73-

5 **Example 186**

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-phenylethyl)amino]carbonyl}amino}propanoic acid.

10 **Example 187**
(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(octylamino)carbonyl]amino}propanoic acid.


15 **Example 188**
(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-methoxyanilino)carbonyl]amino}propanoic acid.

20 **Example 189**
(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(anilinocarbonyl)amino]propanoic acid.

20

-74-

Table 11



Ex.	R1	LC @ 254 nm	(M+H) ⁺	Ex.	R1	LC @ 254 nm	(M+H) ⁺
187		4.18 min	481	182		3.26 min	487
189		3.29 min	445	175		3.46 min	481
183		3.32 min	451	176		3.48 min	525
185		3.20 min	459	177		3.81 min	521
173		3.32 min	459	181		3.39 min	463
178		3.50 min	459	180		3.68 min	481
188		3.27 min	475	184		3.57 min	495
174		3.36 min	475	186		3.37 min	473
				179		3.92 min	529

5 The following compounds were synthesized as described in the above Scheme 6 (Path A), using various resin bound amides in the place of 4-2. These compounds were characterized using LC and MS as shown in Table 12.

Example 190
 (2S)-3-{{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isobutyrylamino)propanoic acid.

-75-

Example 191

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(butyrylamino)propanoic acid.

5

Example 192

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(hexanoylamino)propanoic acid.

10 Example 193

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pentanoylamino)propanoic acid.

Example 194

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[
[(3,3-dimethylbutanoyl)amino]propanoic acid.

Example 195

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid.

Example 196

(2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}-
ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

25

Example 197

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
(pent-4-ynoylamino)propanoic acid.

30 Example 198

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(cyclohexylcarbonyl)amino]propanoic acid.

Example 199

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-
phenylacetyl)amino]propanoic acid.

Example 200

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-
phenylpropanoyl)amino]propanoic acid.

Example 201

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-
cyclohexylacetyl)amino]propanoic acid.

45

-76-

Example 202

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(E)-3-phenylprop-2-enoyl]amino]propanoic acid.

5

Example 203

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-chlorobenzoyl)amino]propanoic acid.

10 **Example 204**

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methylbenzoyl)amino]propanoic acid.

Example 205

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methoxybenzoyl)amino]propanoic acid.

Example 206

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-chlorobenzoyl)amino]propanoic acid.

Example 207

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methylbenzoyl)amino]propanoic acid.

25

Example 208

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxybenzoyl)amino]propanoic acid.

30 **Example 209**

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(pyridin-3-ylcarbonyl)amino]propanoic acid.

Example 210

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(isonicotinoylamino)propanoic acid.

Example 211

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid.

Example 212

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-bromobenzoyl)amino]propanoic acid.

45

Example 213

5 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-
bromobenzoyl)amino]propanoic acid.

Example 214

10 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(2,3-dimethylbenzoyl)amino]propanoic acid.

Example 215

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-
chlorobenzoyl)amino]propanoic acid.

15

Example 216

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
(benzoylamino)propanoic acid.

20 **Example 217**


(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-
ethylbenzoyl)amino]propanoic acid.

Example 218

25 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-
butoxybenzoyl)amino]propanoic acid.

-78-

Table 12



Ex.	R9	LC @ 254 nm	(M+H) ⁺	Ex.	R9	LC @ 254 nm	(M+H) ⁺
190		2.88 min	396 (M+H)	205		3.38 min	460 (M+H)
191		2.88 min	396 (M+H)	206		3.58 min	464 (M+H)
192		3.34 min	424 (M+H)	207		3.45 min	444 (M+H)
193		3.09 min	410 (M+H)	208		3.33 min	460 (M+H)
194		3.24 min	424 (M+H)	209		2.61 min	431 (M+H)
195		3.70 min	450 (M+H)	210		2.58 min	431 (M+H)
196		3.85 min	502 (M+H)	211		3.45 min	448 (M+H)
197		2.84 min	406 (M+H)	212		3.27 min	509 (M+H)
198		3.35 min	436 (M+H)	213		3.65 min	509 (M+H)
199		3.21 min	444 (M+H)	214		3.65 min	458 (M+H)
200		3.42 min	458 (M+H)	215		3.46 min	464 (M+H)
201		3.50 min	450 (M+H)	216		3.19 min	430 (M+H)
202		3.55 min	456 (M+H)	217		3.66 min	458 (M+H)

-79-

203		3.25 min	464 (M+H)	218		4.08 min	502 (M+H)
204		3.29 min	444 (M+H)				

Example 219 (2S)-3-{[4-{[(benzylamino)carbonyl]amino}ethoxy]-2-hydroxybenzoylamino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid (6-4)

5 (2S)-3-{[4-{[(benzylamino)carbonyl]amino}ethoxy]-2-hydroxybenzoylamino}-2-{[(neopentyloxy)carbonyl]amino}propanoic acid on Wang Resin (6-3)

The resin 4-2 (100 mg; 0.1 mmole) was swollen in 1:1 tetrahydrofuran and dichloromethane. To it was added a solution of 4-nitrophenylchloroformate (50 mg; 10 0.25 mmole) in 1:1 THF: DCM (1.5 mL) followed by diisopropylamine (0.075 mL; 0.5 mmole). The reaction mixture was shaken at room temperature for 30 min. The mixture was filtered and the resin was washed with THF (4 x 4 mL) and dichloromethane (4 x 4 mL) and dried. The resin was suspended in DMF (1.5 mL) and benzyl amine (54 mg; 0.5 mmole) was added followed by triethylamine (101 mg; 1 15 mmole). The reaction mixture was shaken at room temperature for 2 h. The mixture were filtered and the resin in each vessel was washed with dimethylformamide (4 x 4 mL), methanol (4 x mL) and dichloromethane (4 x 4 mL). The resin was dried under vacuum.

The resin 6-3 was cleaved by treatment with dichloromethane (0.5 mL) and 20 trifluoroacetic acid (0.5 mL) for 30 min at room temperature. The reaction mixture was filtered and the resin was washed with dichloromethane. The filtrate was concentrated and dried in vacuo on a Savant Speed Vac Plus. This crude product 6-4 was purified via preparative HPLC. NMR (300MHz, MeOH-d4) δ 7.65 (d, J = 7 Hz, 1H), 7.25 (m, 5H), 6.5 (m, 2H), 4.4 (q, 1H), 4.3 (s, 2H), 4.15 (t, 2H), 3.85 (m, 1H), 3.75 (m, 25 3H), 3.5 (t, 2H), 0.9 (s, 9H).

-80-

HR-MS FAB m/z for C₂₆H₃₄N₄O₈ calcd. 531.2455 (M⁺+1), obsd. 531.2459.

The following compounds were synthesized as described in the above Scheme 6 (Path B), using various amines in the place of benzyl amine. These compounds were
5 characterized using LC and MS as shown in Table 13.

Example 220

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(benzyloxy)carbonyl]amino}propanoic acid.

10 Example 221

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(methoxycarbonyl)amino]propanoic acid.

15 Example 222

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(ethoxycarbonyl)amino]propanoic acid.

20 Example 223

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(propoxycarbonyl)amino]propanoic acid.

25 Example 224

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(isopropoxycarbonyl)amino]propanoic acid.

Example 225

(2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[(benzylamino)carbonyl]amino}-
ethoxy)-2-hydroxybenzoyl]amino}propanoic acid.

30 Example 226

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(but-3-enyloxy)carbonyl]amino}propanoic acid.

Example 227

35 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(prop-2-nyloxy)carbonyl]amino}propanoic acid.

Example 228

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(hexyloxy)carbonyl]amino}propanoic acid.

Example 229

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(octyloxy)carbonyl]amino}propanoic acid.

-81-

Example 230

(2S)-3-{[4-(2-[(benzylamino)carbonyl]amino)ethoxy]-2-hydroxybenzoyl]amino}-2-[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

5 **Example 231**

(2S)-3-{[4-(2-[(benzylamino)carbonyl]amino)ethoxy]-2-hydroxybenzoyl]amino}-2-[(butoxycarbonyl)amino]propanoic acid.

10 **Example 232**

10 (2S)-3-{[4-(2-[(benzylamino)carbonyl]amino)ethoxy]-2-hydroxybenzoyl]amino}-2-[(isobutoxycarbonyl)amino]propanoic acid.

15 **Example 233**

15 (2S)-2-[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)-amino)carbonyl]amino)ethoxy]benzoyl}amino)propanoic acid.

20 **Example 234**

20 (2S)-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)amino)carbonyl]-amino)ethoxy]-benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid.

20

Example 235

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)amino)-carbonyl]amino)ethoxy]benzoyl}amino)propanoic acid.

25

Example 236

(2S)-3-({2-hydroxy-4-[1-((pyridin-3-ylmethyl)amino)carbonyl]amino)ethoxy]-benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.

30

Example 237

(2S)-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)amino)carbonyl]-amino)ethoxy]-benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

Example 238

35 (2S)-2-[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)amino)carbonyl]amino)ethoxy]benzoyl}amino)propanoic acid.

Example 239

40 (2S)-2-[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)amino)carbonyl]amino)ethoxy]benzoyl}amino)propanoic acid

40

Example 240

(2S)-3-({2-hydroxy-4-[2-((pyridin-3-ylmethyl)amino)carbonyl]-amino)ethoxy]-benzoyl}amino)-2-[(prop-2-nyloxy)carbonyl]amino}propanoic acid.

-82-

Example 241

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

5 **Example 242**

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid.

10 **Example 243**

10 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid.

15 **Example 244**

15 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid.

20 **Example 245**

(2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

20 **Example 246**

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid.

25 **Example 247**

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

30 **Example 248**

30 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)-ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid.

35 **Example 249**

(2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)-amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

40 **Example 250**

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid.

40 **Example 251**

(2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid.

-83-

Example 252

(2S)-2-{[(allyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

5 **Example 253**

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

10 **Example 254**

10 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(prop-2-ynyl)carbonyl]amino } propanoic acid.

15 **Example 255**

15 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid.

20 **Example 256**

20 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino } propanoic acid.

25 **Example 257**

25 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino } propanoic acid.

30 **Example 258**

30 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino } propanoic acid.

35 **Example 259**

35 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)-ethoxy]benzoyl}amino)propanoic acid.

40 **Example 260**

40 (2S)-3-({2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}-amino)ethoxy]-benzoyl}amino)-2-{[(isobutoxycarbonyl)amino]propanoic acid.

45 **Example 261**

45 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methylbenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid. LC 4.75 min.,

45 M+H 565.

50 **Example 262**

50 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-({[(4-methoxybenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid. LC 3.75 min.,

50 M+H 581.

-84-

Example 263

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-({[(4-chlorobenzyl)amino]-carbonyl}-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 4.83 min., M+H 5.86.

5 Example 264

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(4-{2-[(dimethylamino)benzyl]-amino}carbonyl)amino]ethoxy]-2-hydroxybenzoyl)amino]propanoic acid. LC 3.7 min., M+H 594.

10 Example 265

(2S)-3-[(4-{2-[(4-(aminosulfonyl)benzyl)amino}carbonyl)amino]ethoxy]-2-hydroxybenzoyl)amino]-2-{[(benzyloxy)carbonyl]amino}propanoic acid. LC 4.08 min., M+H 630.

15 Example 266

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2-hydroxy-4-{2-[(4-(trifluoromethoxy)benzyl)amino}carbonyl)amino]ethoxy]benzoyl)amino]propanoic acid. LC 5.06 min., M+H 635.

20 Example 267

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-((2-chlorobenzyl)amino]carbonyl)-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 4.8 min., M+H 586.

Example 268

25 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((2-methylbenzyl)amino)-carbonyl)amino]ethoxy]benzoyl}amino)propanoic acid. LC 4.74 min., M+H 565.

Example 269

30 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-((2-bromobenzyl)amino]-carbonyl)-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 4.85 min., M+H 630.

Example 270

35 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-((2,4-dichlorobenzyl)amino)-carbonyl)amino]ethoxy]-2-hydroxybenzoyl}amino)propanoic acid. LC 5.08 min., M+H 620.

Example 271


40 (2S)-3-({4-[2-((2-aminobenzyl)amino]carbonyl)amino]ethoxy}-2-hydroxybenzoyl)-amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid. LC 3.81 min., M+H 566.

Example 272

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((pyridin-2-ylmethyl)-amino]carbonyl)amino]ethoxy]benzoyl}amino)propanoic acid. LC 3.58 min., M+H 552.

-85-

Table 13




Ex.	221-227	248-254	234-240		219-220 228-232	247 & 255-260	233 & 241-246
R8 → R9 ↓				R8 → R9 ↓	 219-220 & 228-232		
methyl	475 M+H 3.84min 221	476 M+H 2.84min 248	476 M+H 2.84min 234	hexyl	545 M+H 4.90min 228	546 M+H 3.90min 255	546 M+H 3.90min 241
ethyl	489 M+H 4.00min 222	490 M+H 3.01min 249	490 M+H 2.99min 235	octyl	573 M+H 5.37min 229	574 M+H 4.38min 256	574 M+H 4.37min 242
n-propyl	503 M+H 4.21min 223	504 M+H 3.20min 250	504 M+H 3.19min 236	(CH ₃) ₃ CCH ₂ -	531 M+H 4.58min 219	532 M+H 3.57min 257	532 M+H 3.58min 243
i-propyl	503 M+H 4.19min 224	504 M+H 3.17min 251	504 M+H 3.17min 237	(CCl ₃) ₃ CCH ₂ -	593 M+H 4.62min 230	594 M+H 3.62min 258	594 M+H 3.62min 244
allyl	501 M+H 4.14min 225	502 M+H 3.12min 252	502 M+H 3.12min 238	n-butyl	517 M+H 4.43min 231	518 M+H 3.43min 259	518 M+H 3.43min 245
homo- allyl	515 M+H 4.31min 226	516 M+H 3.28min 253	516 M+H 3.29min 239	i-butyl	517 M+H 4.41min 232	518 M+H 3.40min 260	518 M+H 3.40min 246
propargyl	499 M+H 4.06min 227	500 M+H 3.01min 254	500 M+H 3.02min 240	benzyl	551 M+H 4.59min 220	552 M+H 3.52min 247	552 M+H 3.55min 233

5 Alternatively, Schemes 7-12 demonstrate the solution phase synthesis practice of this invention with detailed synthetic procedures for representative compounds.

-86-

Scheme 7.



-87-

Example 273 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid ethyl ester (8-1)

Methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate (7-1)

5

Methyl 2, 4-dihydroxy benzoate (14.5g, Aldrich), 2-(N-t-butoxycarbonyl)ethanol (13.9g, Aldrich) and triphenyl phosphine (22.6g, Aldrich) were combined in 350 mL of THF and cooled in ice under N₂ atmosphere. Diethyl diazodicarboxylate (DEAD, 15g, Aldrich) was added, the ice bath removed and the reaction mixture allowed to 10 stir at ambient temperature for 15h. The solvent was removed on a rotary evaporator and the residue chromatographed on silica gel (300g, Merck silica 60), elution with CH₂Cl₂ to give 18g of methyl 4-[2-N-(t-butoxycarbonyl)ethoxy]-2-hydroxy benzoate, as a viscous oil. NMR (300 MHz, CDCl₃) δ 11.0 (s, 1 H), 9.5 (d, J = 8Hz, 1H), 6.4 (m, 2H), 5.0 (broad, 1H), 4.0 (t, J = 5Hz, 2H), 3.91 (s, 3H), 3.54 (m, 2H), 1.45 (s, 15 9H), MS (+ESI) m/z 334 (M+Na)⁺.

4-(2-Aminoethoxy)-2-hydroxybenzoic acid, hydrochloride (7-2)

Ester 7-1 (7.2g) was treated with 5eq. KOH (dissolved in minimum amount of water 20 and equal volume of 1, 4-dioxane) at room temperature until TLC indicated complete absence of starting material (3-12h). The reaction mixture was acidified (pH = 6) with the addition of 1N HCl solution and extracted with ethyl acetate. The extract was washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated on the rotary evaporator. The crude product (5.34g) was recrystallized 25 from ether, then dissolved in 1, 4-dioxane and treated with an excess of anhydrous HCl (4M in dioxane, Aldrich). The mixture was allowed to stand at ambient temperature for 24h. Volatile materials were removed in vacuo on the rotary evaporator to give 7-2 as a hydroscopic off-white solid. NMR (400 MHz, DMSO-d6) δ 13.6 (broad, 1H), 11.6 (broad, 1H), 8.3 (broad, 3H), 7.7 (d, J = 9 Hz, 2H), 6.53 (m, 30 2H), 4.23 (t, J = 5Hz, 2H), 3.2 (s, broad, 2H).

2-Hydroxy-4-[2-(pyrimidine-2ylamino)ethoxy]benzoic acid (7-3)

A mixture of compound 7-2 (20g), diisopropylethylamine (DIPEA, 74 mL),
5 trimethylsilylchloride (TMSCl, 21.6 mL) and 2-bromopyrimidine (Lancaster, 13.5g)
were combined in 350 mL 1, 4-dioxane at room temperature, then brought to reflux
under N₂ atmosphere. After 2 days, an additional 12 mL trimethylsilyl chloride was
added, and the mixture continued at reflux for an additional 2 days (until TLC showed
no starting material remained). The reaction mixture was cooled to ambient
10 temperature, concentrated to dryness in vacuo on a rotary evaporator and the residue
suspended in water. The heterogeneous mixture was refluxed briefly, allowed to cool
to room temperature, the product collected on a vacuum filter and air dried to give
15.3g of 7-3, as a tan powder. NMR (400 MHz, DMSO-d₆) δ 12 (very broad, 2H)
8.3 (d, J = 5 Hz, 2H) 7.7 (d, J = 9Hz, 1H), 7.28 (t, J = 6Hz, 1H), 6.57 (t, J = 5Hz,
15 1H), 6.49 (m, 2H), 4.13 (t, J = 6Hz, 2H), 3.62 (q, 2H); MS (+ESI) m/z 276 (M+H)⁺ ;
IR (KBr) ν (cm⁻¹) 3275, 3000, 1660, 1625.

A mixture of compound 7-3 (5.51g), N-hydroxybenzotriazole hydrate(HOBt·H₂O,
4.6g, Aldrich), N-methyl morpholine (NMM, 8.8 mL) and 1-[3-(dimethylamino)-
20 propyl]-3-ethyl carbodimide hydrochloride (DEC, 7.6g, Aldrich) were stirred at room
temperature in 60 mL DMF for ~ 0.3 h, followed by the addition of 2(S)-
benzenesulfonylamino-β-alanine ethyl ester (WO9532710, Scheme 2). The mixture
was allowed to stir at room temperature for 2 days under N₂ atmosphere. Volatile
materials were removed in vacuo on a rotary evaporator, and the residue dissolved in
25 ethanol. Twenty grams of silica gel (silica 60, Merck) were added and the solvent
removed. Chromatography on 300g of silica gel (ethyl acetate elution, gave 8.1g of
the title compound as a pale yellow glass, which upon hardening and pulverizing
produced an off-white powder. NMR (400 MHz, DMSO-d₆) δ 12.5 (s, 1H), 8.68 (t, J
= 6Hz, 1H), 8.48 (d, J = 9Hz, 1H), 8.27 (d, J = 5Hz, 1H), 7.73 (m, 2H), 7.64 (d, J =
30 9Hz, 1H), 7.55-7.5 (m, 1H), 7.48-7.44 (m, 2H), 7.27 (t, J = 6Hz, 1H), 6.58 (t, J =


-89-

5Hz, 1H), 6.47 (dd, J = 6Hz, 3Hz, 1H), 6.42 (d, J = 2Hz, 1H), 4.1 (t, J = 6Hz, 2H), 4.05 (q, J = 7Hz, 1H), 3.79 (q, J = 7Hz), 3.62 (q, 2H), 3.54 (m, 1H), 3.34 (m, 1H overlapping with H₂O peak), 0.94 (t, J = 7Hz); MS (+ESI) m/z 530 (M + H)⁺; IR (KBr) ν (cm⁻¹) 3400, 1740, 1650, 1580.

5

10

-90-

Scheme 8

-91-

Example 274 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid (8-2).

To a solution of compound 8-1 (8.1g), dissolved in 75 mL 1, 4-dioxane, was added a
5 solution of NaOH (4g) in 75 mL H₂O and the reaction mixture was stirred at room
temperature for 15h. The mixture was concentrated in vacuo and the residue
partitioned between water and dichloromethane. The aqueous phase was acidified
with 1N aqueous HCl solution to pH 7, which produced a gum precipitate. This
material (7g) was absorbed onto 15g of silica gel as in example 1, followed by
10 chromatography on 200g silica gel. Elution with chloroform (90)-methanol (10)-acetic
acid (0.1) gave the title compound as an amber syrup. MS (-ESI) m/z 500 (M-H)⁺;
[α]_D²⁵ = 6.84 (c. 9.497, methanol).

Analysis for: C₂₂H₂₃N₅O₇S:

Calculated: C, 52.69; H, 4.62; N, 13.96.

15 Found: C, 52.65; H, 4.43; N, 13.6.

Example 275 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride (8-3).

20 A mixture of compound 8-2 (8g) and 10% Pd/C (1g) was stirred at room temperature
in 1, 4-dioxane (125 mL), acetic acid (125 mL), water (50 mL) and concentrated HCl
(2 mL) under H₂ atmosphere (balloon) for 2 days. Celite was added to the mixture
with stirring for 0.25h, and the mixture was filtered through a pad of celite with the aid
of isopropanol. The filtrate was concentrated on the rotary evaporator and the residue
25 treated sequentially with (1)warm heptane, then concentrated; (2) 1:1 water -1, 4-
dioxane, then filtered and concentrated, followed by vacuum drying in an abderhalden
apparatus (isopropanol, reflux) to give the title compound 8-3 (4.7g) as a hygroscopic
white powder. NMR (400 MHz, DMSO-d₆) δ 12.6 (broad, 2H) 8.77 (broad, 1H), 8.2
(broad, 1H), 8.1 (broad, 2H), 7.72 (m, 3H), 7.47-7.37 (m, 3H), 6.46 (m, 1H), 6.44 (s,
30 broad, 1H), 4.07 (t, J = 5Hz, 2H), 3.93 (broad, 1H), 3.63 - 3.43 (m, 1H), 3.4 - 3.25

-92-

(m, 2H), 1.9 - 1.77 (m, 2H); IR (KBr) ν (cm⁻¹) 3360, 1720, 1580; MS (+ESI) m/z 506 (M+H)⁺.

Example 276 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)-5-ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride (8-4)

The above acid (8-3) was dissolved in ethanol (25 mL) and concentrated HCl (1 mL). The mixture was heated to reflux for 15h, concentrated on a rotary evaporator and filtered through a short plug of silica gel with the aid of ethanol to give the title compound as a hygroscopic tan powder. IR(KBr) ν (cm⁻¹) 1745, 1690; MS (+ESI) m/z 534 (M+H)⁺.


Analysis for C₂₄H₃₁N₅O₇S•HCl.

Calculated: C, 50.57; H, 5.66; N, 12.29.

Found: C, 50.71; H, 5.66; N, 12.53

-93-

Scheme 9



Example 277 2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride (9-2).

5

2-Hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoic acid (9-1).

Compound 7-3 (2g) was combined with 10% Pd/C (0.5g), acetic acid (100 mL) and concentrated hydrochloric acid (0.7 mL). The mixture was stirred at room 10 temperature under an atmosphere of H₂ (balloon) for 2 days. Celite was added and the mixture stirred for 0.5h, then filtered through a pad of celite with the aid of isopropanol. Volatile materials were removed on the rotary evaporator and the residue warmed with heptane (~0.5h, 100°C) followed by concentration in vacuo to give 9-1 as a tan foam. NMR (400 MHz, DMSO-d₆) δ 12.9 (broad, 2H), 8.25 (s, broad, 2H), 7.85 (t, J = 6Hz, 1H), 7.66 (d, J = 9 Hz, 1H), 6.48 - 6.41 (m, 2H), 4.07 (t, J = 5Hz, 2H), 3.56 - 3.50 (m, 2H), 3.22 (m, 2H, overlapping with H₂O peak), 1.79 (m, 2H); IR (KBr) v (cm⁻¹) 3450 (broad); MS (+ESI) m/z 280 (M + H)⁺.

Compound 9-1 (1.58g), 3-amino-2(S)-benzylloxycarbonylaminopropionic acid, ethyl 20 ester hydrochloride (1.51g; from the amino acid (Fluka) esterified with HCl in ethanol), N-methyl morpholine (NMM, 1.52g) and benzotriazol-1-yloxytris(dimethylamino) phosphoniumhexafluorophosphate (BOP, 2.21g) were combined in 40 mL anhydrous DMF. The mixture was stirred for 48h at room temperature, additional BOP reagent (1g) was added and the reaction stirred for 15h. 25 Volatile materials were removed on the rotary evaporator, the residue dissolved in ethanol and absorbed onto 20g silica gel, and this added to the top of a 200g silica gel column. Flash chromatography, elution with chloroform-methanol-acetic acid (90:10:1) followed by treatment with an equivalent concentrated aqueous HCl in ethanol and concentration provided the title compound as a hygroscopic tan powder.

30 NMR (400 MHz, DMSO-d₆) δ 12.7 (s, 1H), 8.85 (t, J = 6 Hz, 1H), 8.00 (s, broad,

-95-

2H), 7.84 (d, J = 7.5 Hz, 1H), 7.80 (d, J = 9 Hz, 1H), 7.60 (t, J = 6 Hz, 1H), 7.32 (m, 5H), 6.49-6.45 (m, 2H), 5.02 (s, 2H), 4.27 (q, 1H), 4.06 (m, 4H), 3.66 - 3.55 (m, 2H), 3.49 (m, 2H), 3.23 (m, 4H), 1.79 (m, 2H), 1.10 (t, J = 7 Hz, 3H); IR (KBr) ν (cm⁻¹) 3300, 1730, 1650; MS (+ESI) m/z 528 (M+H)⁺.

5

Example 278 2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride (**9-3**).

The above ester **9-2** was hydrolyzed to the title compound **9-3** by refluxing (15-24h) 10 1N aqueous HCl solution. When TLC indicated no starting ester remained, the solution was concentrated on the rotary evaporator and the residue treated with warm isopropanol, filtered and concentrated to give **9-3** as a hygroscopic tan powder. MS (+FAB) m/z 500 (M+H)⁺; $[\alpha]_D^{25} = -7.83$ (c. 5.36, MeOH).


Analysis for C₂₄H₂₉N₅O₇•HCl•H₂O;

15 Calculated: C, 52.03; H, 5.82; N, 12.64.

Found: C, 52.02, H, 5.53; N, 12.00.

-96-

Scheme 10



Example 279 3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride. (10-4)

Compound 10-1 (1.33g, scheme 7) and β -phenylalanine ethyl ester hydrochloride (1.03g; from ethanol - HCl treatment of β -phenylalanine (Aldrich)) were combined in dichloromethane (20 mL) with DEC coupling agent (0.94g), HOBT (0.75g) and NMM (0.99g). The mixture was stirred at room temperature for 15h. Volatile materials were removed in vacuo on a rotary evaporator and the residue partitioned between ethyl ether and 1N aqueous HCl solution. The organic phase was washed with saturated aqueous brine solution, dried over $MgSO_4$, filtered and concentrated to give 2.8g of crude coupling product 10-2 (Scheme 10). The N-terminal Boc group was removed by dissolving the product in a minimum amount of absolute ethanol and adding an equal volume of anhydrous HCl in 1, 4-dioxane (4M, Aldrich). This mixture was allowed to stand at room temperature for 15h, concentrated in vacuo on a rotary evaporator, and treated with an excess of 5 eq. of the theoretical amount of KOH (~1.7g, ~85%, Baker) in water (20 mL) at reflux for 24h. The mixture was cooled to room temperature and acidified with 1N HCl solution to pH 6. 3,5-Dimethylpyrazol-1-carboxamidine nitrate (1g, Aldrich) and 0.75g of $NaHCO_3$ were added and the mixture refluxed for 15h. An additional 0.2g carboxamidine were added, and reflux continued for 3h, when TLC ($MeOH:CHCl_3:NH_4OH$ (2:8:0.1)) indicated complete conversion of 10-3 (lower spot) to product 10-4 (upper spot). The reaction mixture was concentrated on the rotary evaporator, and the residue slurried in a mixture of $MeOH:CHCl_3:NH_4OH$ (3:7:0.1). Anhydrous Na_2SO_4 was added and the mixture was stirred at room temperature for 12h, filtered and concentrated to give 3.4g of crude guanidino acid 10-5. This material was chromatographed on silica gel (50g), elution with $MeOH:CHCl_3:NH_4OH$ (2:8:0.1) to give 0.65g of 10-5, contaminated with inorganic matter (inferred from C,H,N analysis). This material was treated with concentrated HCl (0.5 mL) in absolute ethanol (10 mL) at reflux for 15h, cooled to room temperature, concentrated, dissolved in EtOH (95:5), dried ($MgSO_4$), filtered and concentrated to give 0.34g of the title compound as a hygroscopic tan powder.

-98-

NMR (400 MHz, DMSO-d₆) δ 12.78 (s, 1H), 9.15 (d, J = 8Hz, 1H), 7.93 (d, J = 9 Hz, 1H), 7.84 (t, J = 6 Hz, 1H), 7.37 (d, J = 7 Hz, 2H), 7.32 (t, J = 7Hz, 2H), 7.25 (m, 1H), 7.1 - 7.6 (broad, 3H), 7.11 (s, broad 1H), 6.5 (dd, J = 6 Hz, 2.6 Hz, 1H), 6.44 (d, J = 2.6 Hz, 1H), 5.48 (q, A portion of an AMX, J_{AM} = 4Hz, 1H), 4.07 (t, J = 5Hz, 2H), 4.0 (m, 2H), 3.53 (m, 2H), 3.03 (q, M portion of an AMX, J_{MX} = 16 Hz, 2H), 2.89(q, X portion of an AMX, J_{AX} = 6 Hz, 2H), 1.08 (t, J = 7 Hz, 3H); (KBr) v (cm⁻¹) 3350, 3180, 1745, 1690; MS(+FAB) m/z 415 (M+H)⁺.

Analysis for C₂₁H₂₆N₄O₅•HCl•5H₂O
Calculated: C, 54.85; H, 6.14; N, 12.18.
10 Found: C, 54.54; H, 6.04; N, 12.58.


Example 280 3-[4-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid, hydrochloride (**10-5**)

15

Ester **10-4** was refluxed in 1N HCl for 15h. The reaction was cooled and concentrated in vacuo to provide the title compound as a hygroscopic tan powder.
MS (-FAB) m/z 385 (M-H)⁺; IR (KBr) v (cm⁻¹) 3350, 3180, 1720, 1590.
Analysis for C₁₉H₂₂N₄O₅•HCl•H₂O
20 Calculated: C, 51.76; H, 5.72; N, 12.71
Found: C, 51.76; H, 5.74; N, 12.77.

-99-

Scheme 11



-100-

Example 281 3-[2-Hydroxy-4-[2-(pyrimidin-2ylamino)ethoxy]-benzoylamino]-3-pyridine-3-ylpropionic acid ethyl ester (**11-2**).

3-[4-(2-aminoethoxy)-2-hydroxy-benzoylamino]-3-pyridine-3-yl-propionic acid ethyl ester dihydrochloride (**11-1**).

Compound **10-1** (2.05g; see Scheme 1), 3-amino-3-(pyridine-3yl, propionic acid ethyl ester dihydrochloride (1.84g; see J. Org. Chem. 1993, 58, 7948), NMM (2.58g), HOBr (1.16g), and DEC (1.45g) were combined in dichloromethane (50 mL) and stirred at room temperature for 60 h. Volatile materials were removed on the rotary evaporator, the residue partitioned between ether and H₂O, the organic phase washed with saturated aqueous brine solution, dried over MgSO₄, filtered and concentrated to give 3.52g of crude coupled product, which was dissolved in a minimum amount of ethanol and treated with an excess of 4M HCl in anhydrous dioxane (Aldrich). After standing overnight (~15 h), volatile materials were removed on the rotary evaporator to give 3.31g of **11-1**. NMR (400 MHz, DMSO-d₆) was consistent with the structure of **11-1**; MS (+ FAB) m/z 374 (M + H)⁺.

Compound **11-1** (3.31g), 2-bromopyrimidine (1.11g, Lancaster) and DIPEA (7.5 mL) were combined in dioxane (50 mL) at room temperature under N₂. Chlorotri-methylsilane (1.89 mL) was added and the mixture was brought to reflux. Stirring continued at this temperature for 4 days. The mixture was concentrated on the rotary evaporator, and the residue partitioned between aqueous HCl solution and chloroform. The aqueous phase was concentrated to a dark oil and the pH adjusted to 7 with aqueous ammonia. Volatile materials were removed in vacuo and the residue chromatographed on 200g of silica gel, elution with ethyl acetate to give 1.37g of the title compound, as an off-white powder. NMR (400 MHz, DMSO-d₆) was consistent with the structure of **11-2**; (KBr) ν (cm⁻¹) 1720; MS (+FAB) m/z 452 (M+H)⁺.

Analysis for C₂₃H₂₅N₅O₅•0.5H₂O

Calculated: C, 59.99; H, 5.69; N, 15.21

Found: C, 60.45; H, 5.61; N, 14.79.

-101-

Example 282 3-[2-Hydroxy-4-[2-(3, 4, 5, 6 - tetrahydropyrimidine-2ylamino)-ethoxy]benzoylamino]-3-pyridin-3-ylpropionic acid (5-3).

A mixture of compound 11-2 (0.9g) and KOH (0.34g) were stirred in water-dioxane
5 mixture (1:1) at room temperature. When TLC (EtOAc) showed complete absence of
starting ester, solvents were removed on the rotary evaporator, 10% Pd/C (0.2g,
Aldrich) was added and the mixture suspended in acetic acid (20 mL), dioxane (10 ml),
water (5 ml) and concentrated HCl (0.6 mL). The mixture was stirred at ambient
temperature under H₂ atmosphere (balloon) for 2 days. Celite was added, and the
10 mixture stirred 0.25h, filtered through a pad of celite with the aid of dioxane-water
(1:1), and concentrated. The residue was chromatographed on silica gel (25g), elution
with chloroform-methanol-ammonium hydroxide (7:3:0.1) to give the title compound
11-3 as an off-white hygroscopic powder. NMR (400 MHz, DMSO-d₆ + D₂O) was
consistent with the structure 11-3; IR (KBr) ν (cm⁻¹) 3400, 1650 (broad), 1580; MS
15 (+FAB) m/z 428 (M+H)⁺.

Example 283 3-[2-Hydroxy-4-[2-(3, 4, 5, 6 -tetrahydropyrimidin - 2-ylamino)ethoxy]
benzoylamino]-3-pyridin-3-ylpropionic acid ethyl ester dihydrochloride (11-4).


20 A sample of the above zwitterion 11-3 (0.285g) was esterified with absolute ethanol-
HCl mixture at reflux. Concentration on the rotary evaporator gave the title
compound 11-4. NMR (400 MHz, DMSO-d₆) δ 12.55 (s, broad, 1H), 9.5 (d, J =
8Hz, 1H), 8.94 (d, J = 2Hz, 1H), 8.73 (m, 1H), 8.48 (d, J = 2 Hz, 1H), 8.73 (m, 1H),
8.48 (d, J = 8 Hz, 1H), 8.1 (s, broad, 2H), 7.99 (d, J = 9 Hz, 1H), 7.86 (m, 1H), 7.68
25 (t, J = 6Hz, 1H), 6.5 (d, J = 2 Hz, 1H), 6.47 (m, 1H), 5.58 (q, A portion of an AMX,
 $J_{AM} = 14$ Hz, 1H), 4.08 - 4.0 (overlapping m, 4H), 3.5 (m, 2H), 3.25 - 3.19
(overlapping m, 3H), 3.09 (q, X portion of an AMX, $J_{MX} = 16$ Hz, $J_{AX} = 6$ Hz, 1H),
1.79 (m, 2H), 1.08(t, J = 7 Hz, 3H).

Analysis for C₂₃H₂₉N₅O₅•2HCl•0.7 H₂O.

30 Calculated: C, 51.39; H, 6.00; N, 13.03.
Found: C, 51.40; H, 6.01; N, 12.56.

-102-

Scheme 12



a) KOH, ²O, then ²O; ¹⁰H₁₅(CH₂)₃O(CO)O₆H₄NQ, ³CN, then
HR-MS FAB m/z for C₂₆H₃₄N₄O₈ calcd. 531.2455 (M⁺+1), obsd. 531.2459.

Example 284 2(S)-2-tert-Butoxycarbonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoylamino}propionic acid, (12-4) acetic acid salt.

5

Compound 12-1 (2.43g, scheme 12; obtained as for compound 8-1, Scheme 8, by substituting 2(S)-2-benzyloxycarbonylamino-3-amino propionic acid ethyl ester (from esterification of the acid (Fluka) using EtOH-HCl) for 2(S)-2-phenylsulfonylamino-3-amino propionic acid) and NaOH (4g) in 1,4-dioxane-water (~1:1) were refluxed for 10 1.5h. The mixture was cooled and volatile materials removed on the rotary evaporator. The residue was neutralized with aqueous 1N HCl and stirred overnight at room temperature. The precipitate was collected by vacuum filtration, re-esterified (EtOH-HCl, reflux), and chromatographed on silica gel, elution with CHCl₃/MeOH/HOAc (90:10:1→80:20:2) to give 850 mg of 12-2, as a tan powder.

15

The ester 12-2 (0.5g) was hydrolyzed with excess KOH in dioxane-H₂O at room temperature. When TLC analysis indicated an absence of starting material, an excess of di-tert-butyl dicarbonate was added and the mixture stirred at room temperature until complete by TLC. The mixture was concentrated on the rotary evaporator and 20 the residue chromatographed on silica gel, elution with CHCl₃/MeOH/NH₄OH (90:1:1→80:20:2) to give 200 mg of 12-3. This material was dissolved in a minimum amount of acetic acid, then diluted with an ~ volume of dioxane-H₂O (2:1). Hydrogenation (5% Pd/C (catalytic), H₂, balloon, rt,) was complete within 2 days. The catalyst was filtered, and the filtrate concentrated on the rotary evaporator. The 25 residue was stirred/concentrated sequentially with heptane and isopropanol, dissolved in CHCl₃ and treated with a mixture of activated charcoal and celite, filtered and concentrated to give the title compound 12-4 (0.18g) as a fine buff powder. NMR (400 MHz, DMSO-d₆) δ 8.85 (broad, 1H), 8.6 (broad, 1H), 8.4 (broad, 1H), 7.68 (d, J = 8.8 Hz, 1H), 6.47 (overlapping peaks, 2H), 6.4 (d, J = 8.8Hz, 1H) 4.02 (t, broad, 30 2H), 3.88 (m, 1H), 3.45 (m, overlapping, 4H), 3.23 (m, broad, 4H), 1.9 (s, 3H), 1.8

-104-

(m, broad, 2H), 1.35 (s, 9H); IR (KBr) ν (cm^{-1}) 3400 (broad), 1710, 1640; MS (ESI-) m/z 464 (M-1)+. Analysis for $\text{C}_{21}\text{H}_{31}\text{N}_5\text{O}_7 \bullet \text{HOAc} \bullet \text{H}_2\text{O}$

Calculated: C, 50.82; H, 6.86; N, 12.88

Found: C, 50.96; H, 6.56; N, 12.11

5 HPLC analysis of purity: 96.8%

In like manner, examples 284-315 (Table 14) were prepared, using the synthetic methods outlined above, as indicated by scheme numbers in the table. All final products were characterized as in Examples 1-283, and had spectra consistent with the assigned
10 structures.

Table 14. Examples 284-315

I

Am = Amidino
 Pyr = pyrimidin-2-yl
 Thp = tetrahydropyrimidine
 Ph = phenyl
 Py = 3-pyridin-3-yl
 Cbz = benzoyloxycarbonyl

Example	No.	#	G	n	R ¹	R ²	R ³	R ⁴	R ⁵	Synth.	Method	Description
	284	4	Am	1	H	H	Py	H	Ei	10	brown powder	
	285	4	Am	1	H	H	Py	H	H	10	buff powder	
	286	4	Pyr	1	H	H	Py	H	H	11	yellow powder	
	287	4	Pyr	1	H	H	Ph	H	H	8	yellow powder	
	288	4	Pyr	1	H	H	Ph	H	Ei	8	white wax	
	289	5	Pyr	1	H	H	Ph	H	H	8	tan powder	
	290	5	Pyr	1	H	H	Ph	H	Ei	8	gold powder	
	291	4	Thp	1	H	H	Ph	H	H	8	buff powder	
	292	4	Thp	1	H	H	Ph	H	Ei	8	buff powder	
	293	5	Thp	1	H	H	Ph	H	H	8	buff powder	
	293	5	Thp	1	H	H	Ph	H	Ei	8	tan powder	
	295	4	Thp	1	H	H	H	NH ₂	H	8	off-white powder	
	296	4	Pyr	1	H	H	H	NHCbz	Me	8	white powder	
	297	4	Pyr	1	H	H	H	NHCbz	H	8	crystalline white powder	
	298	4	Pyr	1	Me	H	H	NHSO ₂ Ph	H	8	yellow powder	
	299	4	Pyr	1	H	H	H	NHCbz	Ei	8	white solid mp 124-125°C	

Table 14 (Continued)

300	5	Thp	3	H	H	H	H	H	H	H	H	H	H	H	H	H	H	H	12	
301	5	Pyr	3	H	H	H	H	H	H	H	H	H	H	H	H	H	H	8	8	
302	5	Pyr	3	H	H	H	H	H	H	H	H	H	H	H	H	H	H	8	8	
303	5	Pyr	4	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
304	5	Thp	4	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
305	5	Thp	4	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
306	4	Pyr	3	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
307	4	Thp	3	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
308	4	Thp	3	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
309	5	Thp	3	H	H	H	H	H	NHSO ₂ Ph	H	H	H	H	H	H	H	H	8	8	
310	4	Thp	2	H	H	H	H	H	NHSO ₂ Ph	t-Bu	8 ^a	8 ^a								
311	4	Thp	2	H	H	H	H	H	NHSO ₂ Ph	(CH ₃) ₂ O	8 ^b	8 ^b								
312	4	Thp	2	H	H	H	H	H	NHSO ₂ Ph	(CH ₃) ₂ NH-BOC	8 ^c	8 ^c								
313	4	Thp	2	H	H	H	H	H	NHCO ₂ -	H	H	H	H	H	H	H	H	12	fine tan powder	
314	4	Thp	2	H	H	H	H	H	CH ₂ CH ₂ C ₁₀ H ₁₅	H	H	H	H	H	H	H	H	12	fin tan powder	
315	4	Thp	2	H	H	H	H	H	NHCO ₂ C ₁₀ H ₁₅	H	H	H	H	H	H	H	H	8 ^d	tan powder	

Vitronectin Receptor $\alpha_v\beta_3$ Binding Assay

The purpose of this assay is to measure the effect of various compounds on the $\alpha_v\beta_3$ - ligand interaction.

5

Reagents

10

Plasma Membrane Isolation: 15 confluent T150 flasks of 512P5 cells ($\alpha_v\beta_3$ - overexpressing cell line) are washed 2X with Dulbecco's phosphate buffered saline (D-PBS) without calcium or magnesium, pH 7.1. Cells are harvested with 10 mL of trypsin/EDTA and collected by centrifugation. The cell pellet is washed 2X with 0.5 mg/mL of soybean trypsin inhibitor, and resuspended at 10% weight/volume in homogenization buffer (25 mM Tris-HCl, pH=7.4; 250 mM sucrose). The cell suspension is homogenized with 2x30 seconds bursts of a Polytron homogenizer. The homogenate is centrifuged at 3000g for 10 minutes at 4 C. The supernatant is collected, measured, and made 100 mM in NaCl and 0.2 mM in MgSO₄. The supernatant is centrifuged at 22,000g for 20 minutes at 4 C, the pellet is resuspended in 7 mL of membrane buffer (25 mM Tris-HCl, pH=7.4; 100 mM NaCl; 2 mM MgCl₂) by 5 strokes of a Dounce homogenizer (tight pestle) and recentrifuged at 22,000g for 20 minutes at 4 C. The pellet is resuspended in 0.5 mL/flask of membrane buffer (stock membranes) and frozen at -80C. Prior to use, stock membranes are Dounce homogenized and diluted 2 μ L to 1000 μ L in membrane buffer.

15

20

25

Compound Dilution: The stock compounds are dissolved in an appropriate vehicle (typically DMSO) and subsequently diluted in assay buffer composed as follows: 25 mM Tris-HCl (pH=7.4), 100 mM NaCl, 2 mM MgCl₂, 0.1% BSA.

Plate Preparation

30

Wells of Multiscreen-FB assay plates (Millipore MAFB NOB 50) are blocked with 150 mL of 0.1% polyethylenimine for 2 hours at

-108-

4° C. Following incubation the wells are aspirated and washed with isotonic saline solution.

Binding Assay

5 125 µL of assay buffer is added to each well. Next, 25 µL of labeled ligand is added to each well. 25 µL of unlabeled ligand is added to non-specific binding wells (NSB). 25 µL of assay buffer is added to all other wells. 2 µL of compound is added to appropriate sample wells, and 2 µL of DMSO is added to NSB and total binding (TB) wells. Finally, 25 µL of membrane is added to each well.

10 The plates are covered and incubated at 37° C for 2 hours in a humidified incubator. Wells are aspirated on a Millipore vacuum manifold, and the wells are washed with 150 µL isotonic saline solution. Wells are again aspirated. The plates are then dried for 1 hour in an 80° C vacuum drying oven. Plates are placed on a Millipore filter punch apparatus, and filters are placed in 12 x 75 mm polypropylene culture tubes. The samples are counted on a Packard gamma counter.

15

Example

20 Using ¹²⁵I- Echistatin (specific activity = 2000 Ci/mmol) supplied by Amersham at a final concentration of 50pM, the following parameters are routinely observed:

Input	80000 cpm
Total Counts	8000 cpm
Non-specific binding	200 cpm

25

Analysis of Results:

30 The individual well activity is expressed as a percentage of the specific binding; % Max, and reported as the mean ± standard deviation. Dose-inhibition relationships are generated for dose (X-axis) vs. % Max (Y-axis) for active compounds using a non-linear regression

-109-

computer program (PS-NONLIN), and IC₅₀ values with corresponding 95% confidence intervals are estimated from 50% of maximal attachment.

Results are shown in Table 15 (VnR).

5 Reference Compounds:

10

Various Arginine-Glycine-Aspartic Acid (RGD)-containing peptides were assessed for the ability to inhibit $\alpha_v\beta_3$ binding and the corresponding IC₅₀ values with 95% confidence intervals were generated; peptide structures are given by the standard single letter designation for amino acids. Values obtained compared favorably with adhesion assay results.

15

20

Peptid	IC ₅₀ (μ M)	95% Confidence Interval
GPenGRGDSPCA	0.064	0.038 to 0.102
GRGDSP	1.493	1.058 to 2.025
GRGDTP	0.490	0.432 to 0.556
GRGDS	0.751	0.690 to 0.817
RGDS	1.840	1.465 to 2.262
GRGDNP	0.237	0.144 to 0.353
GdRGDSP	0.692	0.507 to 0.942
GRGESP	inactive at 100 μ M	

References

25

1. Nesbitt, S. A. And M. A. Horton, (1992), A nonradioactive biochemical characterization of membrane proteins using enhanced chemiluminescence, *Anal. Biochem.*, 206 (2), 267-72.

30

Osteopontin- $\alpha_v\beta_3$ Cell Attachment Assay

The purpose of this assay is to measure the effect of various compounds on the RGD-dependent attachment of cells to osteopontin mediated by the $\alpha_v\beta_3$ integrin.

-110-

Reagents

Cell Suspension Media: The cells are suspended for assay in the tissue culture media used for normal culture maintenance buffered with 25 mM HEPES (pH 7.4) without serum supplementation.

5 Compound Dilution Media: The stock compounds are dissolved in an appropriate vehicle (typically DMSO) and subsequently diluted in the tissue culture media used for normal culture maintenance buffered with 25 mM HEPES (pH 7.4) supplemented with 0.2% BSA (no serum); final vehicle concentration is \leq 0.5%.

10 Plate Preparation

Human recombinant osteopontin (prepared such as described in Stubbs, J. III, Connective Tissue Research, 1996, 35 (1-4), 393-399 is diluted to an appropriate concentration in Dulbecco's phosphate buffered saline (D-PBS) without calcium or magnesium, pH 7.1. 100 mL of this solution is incubated in the wells of PRO-BIND assay plates (Falcon 3915) for 2 hours at 37° C. Following incubation the wells are aspirated and washed once with D-PBS; plates can either be used immediately or stored for up to 1 week at 4° C. Prior to assay, the wells are blocked with 1% bovine serum albumin (BSA) in cell suspension media for 1 hour at 37° C. Following the blocking period, wells are aspirated and washed once with D-PBS.

20 Cell Suspension

25 $\alpha\beta_3$ -expressing cell lines are maintained by standard tissue culture techniques. For assay, the cell monolayer is washed three times with D-PBS, and the cells are harvested with 0.05% trypsin/0.53 mM EDTA (GIBCO). The cells are pelleted by low-speed centrifugation and washed three times with 0.5 mg/mL trypsin inhibitor in D-PBS (Sigma). The final cell pellet is resuspended in cell suspension media at a concentration of 10^6 cells/mL.

-111-

Attachment Assay

5

Incubation: 100 mL of diluted test compound is added to osteopontin-coated wells (in triplicate) followed by 100 mL of cell suspension; background cell attachment is determined in uncoated wells. The plate is incubated at 25° C in a humidified air atmosphere for 1.5 hours. Following the incubation period, the wells are gently aspirated and washed once with D-PBS.

10

15

Cell Number Detection: The number of cells attached is determined by an MTT dye conversion assay (Promega) according to the manufacturer's instructions. Briefly, MTT dye is diluted in cell suspension media (15:85) and 100 mL is added to each well. The assay plates are incubated for 4 hours at 37° C in a humidified 5% CO₂/95% air atmosphere, followed by the addition of 100 mL stopping/solubilization solution. The assay plates are covered and incubated at 37° C in a humidified air atmosphere overnight. After the solubilization period, the optical density of the wells is measured at a test wavelength of 570 nM with a reference measurement taken simultaneously at 630 nM.

20

25

The individual well optical density is expressed as a percentage of the maximal attachment (% Max) wells minus background attachment, and reported as the mean \pm standard deviation. Dose-inhibition relationships are generated for dose (X-axis) vs. % Max (Y-axis) for active compounds using a non-linear regression computer program (PS-NONLIN), and IC₅₀ values with corresponding 95% confidence intervals are estimated from 50% of maximal attachment. Results are shown in Table 16 ("cell").

30

Reference Compounds:

Various Arginine-Glycine-Aspartic Acid (RGD)-containing peptides, and monoclonal antibodies (Chernicon, Temecula, CA) were assessed for the ability to inhibit osteopontin-avb₃ attachment and the corresponding IC₅₀ values with 95% confidence intervals were generated in the SK-MEL-24 human malignant melanoma cell line;

-112-

peptide structures are given by the standard single letter designation for amino acids:

	Peptide	IC50 (95% Confidence Interval)	-
5			
	<u>GPenGRGDSPCA</u>	0.58 mM (0.51 TO 0.67)	
	n-Me-GRGDSP	4.0 mM (3.4 TO 4.7)	
	GRGDSP	4.1 mM (3.4 TO 4.9)	
	GRGDTP	5.2 mM (3.4 TO 4.9)	
10			
	Antibody	Dilution	% Maximal Attachment
			(mean \pm SD)
	$\alpha_v\beta_5$ (P1F6)	1:1000	111 \pm 3.3
		1:100	112 \pm 2.6
15		1:10	111 \pm 3.3
	$\alpha_v\beta_3$ (LM609)	1:1000	0
		1:100	5.1 \pm 1.7

20 Literature References:

Ruoslahti, R. Fibronectin and its receptors. *Ann. Rev. Biochem.* 57:375-413, 1988.

Hynes, R.O. Integrins: Versatility, modulation, and signaling in cell adhesion. *Cell.* 69: 11-25, 1992.

-113-

Osteoclast Pitting Assay

The assay is conducted as described in Murrills and Dempster (1990). Briefly,
4 x 4 x 0.2mm slices of devitalized bovine cortical bone are numbered, placed in the
5 wells of 96-well culture plates and wetted with 100ul of Medium 199 containing
Hanks salts, 10mM HEPES, pH 7.0 (Medium 199/Hanks). Bone cell suspensions
containing osteoclasts are prepared by mincing the long bones of neonatal rats
(Sprague-Dawley , 4-6 days old) in Medium 199/Hanks. 100uL of the suspension is
then plated onto each slice and incubated 30 minutes to allow osteoclasts to adhere.
10 The slices are rinsed to remove non-adherent cells and incubated 24h in Medium 199
containing Earle's salts, 10mM HEPES and 0.7g/L NaHCO₃, which equilibrates at pH
6.9 in a 5% CO₂ atmosphere. At this pH the adherent osteoclasts excavate an
adequate number of resorption pits for assay purposes. Slices are fixed in 2.5%
15 glutaraldehyde and osteoclasts counted following tartrate-resistant acid phosphatase
staining. In experiments in which osteoclast numbers are significantly reduced in a
particular treatment, a check is made for non-specific cytotoxicity by counting the
number of contaminant fibroblast-like cells following toluidine staining. All cells are
stripped from the slice by sonication on 0.25M NH₄OH and the resorption pits formed
by the osteoclasts during the experiment stained with toluidine blue. Resorption pits
20 are quantified by manually counting.

Statistics

The experiments are conducted according to a block design with osteoclasts
25 from each animal exposed to each treatment. Three replicate slices are used per
treatment per animal, such that a total of 96 slices are examined for an experiment
involving four animals and eight treatments (including control). Several parameters are
recorded on a "per slice" basis: number of pits, number of osteoclasts, number of pits
per osteoclast, number of fibroblast-like bone cells. SAS or JMP statistical software is
30 used for statistical analysis. If analysis of variance reveals significant effects in the

experiment, those treatments differing significantly from control are identified using Dunnett's test. IC₅₀s are calculated for active compounds using dose-response curves. Results are shown in Table 16 ("Bone Pitting").

Reference Compound: Rat calcitonin.

5 Clinical Relevance:

Osteoclasts are responsible for the bone loss that occurs in the onset of osteoporosis and anti-resorptive drugs directed against the osteoclast are a requirement for patients losing bone. Calcitonin and bisphosphonates, both used as anti-resorptives in the clinic, show significant osteoclast inhibitory activity in this
10 assay. Hence it is a reasonable assay in which to identify novel anti-resorptives.

Reference: Murrills and Dempster (1990) *Bone* 11:333-344.

Effects of test compounds on PTH-induced hypercalcemia of thyro-parathyroidectomized male rats.
15

Male thyro-parathyroidectomized (TPTX) rats (Charles River) were randomly assigned to groups of 7 rats/group. Following a baseline serum calcium determination an Alzet 1003D minipump (Alza Corporation, Palo Alto, CA) loaded with 0.3 mg/ml PTH (Bachem, Philadelphia, PA) was implanted subcutaneously in each rat. For
20 evaluation of prophylactic effects of a test drug, another minipump with appropriate concentration of the test drug solution was implanted subcutaneously at a site away from PTH minipump. Alternatively, test drugs were administered by oral gavage as a solution or uniform suspension in an appropriate medium depending on the physical properties of the test compound. A group of 7 unimplanted TPTX rats was set aside
25 as a normal control group. Twenty hours after minipump implantation blood was collected from each rat to confirm the presence of hypercalcemia (judged by elevation of serum calcium levels, 2 SD > normal non-implanted level). At various intervals between 0.5 and 24 hours after dosing (usually one to three time points), blood was collected from each rat and the serum evaluated for total calcium. Serum calcium
30 levels were measured using the Nova 7 + 7 calcium auto analyzer spectrophotometrically using the Sigma test kit (#587A). Test results were

-115-

determined by the difference in serum calcium between vehicle and treatment group following PTH administration, using a one-way analysis of variance with Dunnett's test or other multiple comparison methods. Results are shown in Table 17.

5 References:

1. Takeuchi M, Sakamoto S, Kawamuki K, Kudo M, Abe T, Fujita S, Murase K, and Isomura Y, (1990). Synthesis and structure activity relationship of new bisphosphonate derivative. Abstract #53, 199th American Chemical Society Meeting, Boston, MA.
- 10 2. Fisher J, Caulfield M, Sato M, Quartuccio H, Gould R, Garsky V, Rodan G, Rosenblatt M, (1993). Inhibition of osteoclastic bone resorption *in vivo* by echistatin, an "arginyl-glycyl-aspartyl" (RGD) -containing protein. *Endocrinology*, Vol. 132 (3) 1411-1413.

15

Table 15
Representative Biological Data

Example	VnR (IC ₅₀ μM)	Example	VnR(IC ₅₀ μM)
1	0.0241	137	>1uM
2	0.187	138	0.361
3	0.123	139	>1uM
4	0.095	140	0.0978
5	0.061	141	>1uM
6	0.108	142	1.6
7	0.092	143	4.79
8	>1uM	144	
9	0.11	145	
10	0.061	149	
11	0.0696	150	
12	0.0661	151	
13	0.1828	152	
14	0.0445	153	2.4

-116-

Example	VnR ($\text{IC}_{50}\mu\text{M}$)	Example	VnR($\text{IC}_{50}\mu\text{M}$)
15		154	
16		155	
17		156	0.25
18		157	
19		158	4.6
20	1.437	159	2
21	1.516	160	0.97
22		161	0.9
23	1.0216	162	1.1
24	1.48	163	1.1
25	0.6743	164	0.61
26		165	0.39
27	0.3308	166	0.8
28	0.159	167	2.6
29	0.405	168	
30	1.27	169	
31	0.261	170	
32		171	
33		172	
34		173	4.28
35		174	3.89
36		175	3.8
37		176	2.14
38		177	4.87
39		178	3.13
40		179	>1uM
41		180	19.46
42		181	19.72
43		182	40.88
44		183	4.98
45		184	17.88
46		185	4.57
47		186	6.99

-117-

Example	VnR ($\text{IC}_{50}\mu\text{M}$)	Example	VnR ($\text{IC}_{50}\mu\text{M}$)
48		187	19.46
49		188	12.14
50		189	6.87
51		190	>1uM
52		191	>1uM
53	34	192	>1uM
54	34	193	>1uM
55	100.6	194	>1uM
56	85.8	195	>1uM
57		196	5.7127
58	100	197	>1uM
59	100	198	>1uM
60		199	14.694
61		200	>1uM
62	100	201	13.215
63		202	>1uM
64		203	14.136
65	100	204	7.4788
66	100	205	>1uM
67	100	206	>1uM
68	100	207	>1uM
69	100	208	>1uM
70	100	209	>1uM
71	>1uM	210	>1uM
72	>1uM	211	>1uM
73	>1uM	212	13.066
74	>1uM	213	>1uM
75		214	2.3125
76		215	>1uM
77		216	
78	>1uM	217	
79	>1uM	218	
80	>1uM	219	1.8

-118-

Example	VnR ($IC_{50}\mu M$)	Example	VnR($IC_{50}\mu M$)
81	>1 μM	220	8.8
82	>1 μM	221	22.8
83	>1 μM	222	20.8
84		223	5.5
85	>1 μM	224	4.1
86	>1 μM	225	5
87	>1 μM	226	5.2
88	>1 μM	227	5.1
89		228	10.2
90	>1 μM	229	17.1
91	>1 μM	230	4
92	>1 μM	231	6.7
93	>1 μM	232	3.7
94	>1 μM	233	3.3
95	0.105	234	8.7
96	0.119	235	3
97	0.77	236	1.9
98	0.15	237	2.7
99	0.088	238	
100	0.079	239	2.1
101	0.094	240	
102	0.069	241	4.1
103	0.21	242	7.9
104	0.086	243	0.69
105	0.135	244	1.6
106	0.114	245	
107	0.13	246	1.6
108	1.105	247	5.5
109	0.251	248	
110	0.544	249	
111	0.856	250	
112	1.092	251	
113	3.026	252	

-119-

Example	VnR ($\text{IC}_{50}\mu\text{M}$)	Example	VnR ($\text{IC}_{50}\mu\text{M}$)
114	3.139	253	
115	0.258	254	
116	2.761	255	5.31
117	1.518	256	9.08
118	>1uM	257	1.26
119	>1uM	258	4.31
120	>1uM	259	
121	>1uM	260	
122	>1uM	261	20.18
123	>1uM	262	12.64
124	0.734	263	29.03
125	>1uM	264	59.27
126	>1uM	265	12.88
127	0.9546	266	29.57
128	>1uM	267	10.16
129	0.6349	268	33.44
130	>1uM	269	21.23
131	0.4055	270	21.66
132	0.9625	271	13.7
133	>1uM	272	10.63
134	>1uM	273	
135	>1uM	274	
136	>1uM	275	
		276	
		277	
		278	
		279	0.013
		280	12.3
		281	inactive
		282	-42%@100
		283	123
		284	inactive
		285	5

-120-

Example	VnR (μM)	Example	VnR (μM)
		286	2.8
		287	0.26
		288	0.003 bone pitting IC ₅₀ =0.44 μM
		289	inactive
		290	0.334
		291	0.44
		292	0.115
		293	0.006
		294	0.0035
		295	0.0018

Table 16. In Vitro Biological Data

Example No.	Cell ^A	IC ₅₀ (μM)
		Bone Pitting ^B
280	78	inactive @200
297	50	25
277	0.05	0.4
278	0.02	0.5
274	18	0.9
293	48	
276	0.12	0.15
291	28	
275	0.002	0.43
299	inactive @100	1.9
298		
285	56	
286	86	
282	33	
289	34	

5

A Osteopontin - $\alpha_v\beta_3$ Cell Attachment Assay

B Osteoclast Pitting Assay

Table 17. In Vivo Biological Data

Example No.	TPTX (% inhibition)	dose (mg/kg, route)
292	111*	100, s.c.
279	59	100, s.c..
273	57	100, s.c.
277	86*	100, s.c.
	79*	100, p.o.
276	170*	100, s.c.
274	54*	100, s.c.
275	112*	100, s.c.
	(64)	30, s.c.
	105*	75, s.c.
	39	100, p.o.
291	41	100, s.c.
299	102*	100, p.o.

5

* p<0.05 when compared to vehicle control

The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These 10 salts include, but are not limited to, salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and salts with organic acids such as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium. The compounds of the present invention can also be used in the form of 15 esters at the C-terminus; carbamates, amides and the like at the N-terminus or other conventional "pro-drug" forms which, when administered, convert to the active moiety *in vivo*.

Compounds of the present invention may be administered in combination with 20 one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene

glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA. These 5 compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. When administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions, formulations may contain, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, or elixirs containing, for example, from about 20 to 50% 10 ethanol, and the like. When administration is parenterally, formulation may be, for example, sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% by weight of active ingredient in combination with a carrier, and more preferably between about 5% and 60% by 15 weight of active ingredient.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

20

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when compounds of the invention are administered at a daily dosage of from about 0.5 to 25 about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release release form. Preferably, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response as would be 30

-123-


appreciated by one skilled in the art. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

-124-

CLAIMS


What is claimed is:

1. Compounds of the formula



5 wherein:

G is



10

R¹ and R² are independently, hydrogen, alkyl of 1 to 6 carbon atoms, mono or bicyclic aralkyl of 6 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

15

R³ is hydrogen, mono or bicyclic aryl of 6 to 10 carbon atoms, 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O;

20

R⁴ is hydrogen, NHR⁹, OR⁹, NHCO₂R⁹, NHCONHR⁹, NHCOR⁹ or NHSO₂R⁹; provided that R³ and R⁴ are not both hydrogen;

-125-

R⁵ is hydrogen, or alkyl of 1 to 6 carbon atoms, optionally substituted with a terminal group forming a prodrug;

R⁶ and R⁷ are independently hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6

5 carbon atoms, or aralkoxy of 6 to 10 carbon atoms;

R⁸ and R⁹ are independently hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbons, alkynyl of 2 to 10 carbons, mono or polycycloalkyl of 3-12 carbon atoms, mono or polycycloalkyl-alkyl of 4-12 carbon atoms, mono or bicyclic aryl of 6 to 10 10 carbon atoms, 6 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O, mono or bicyclic aralkyl of 7 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

15

n is an integer from 1 to 4; and m is 0 or 1; or a pharmaceutically acceptable salt thereof.

2. Compounds of Claim 1 wherein G is 6-aminopyridin-2yl, pyridin-2yl,

20 pyrimidin-2yl, tetrahydropyrimidin-2yl, tetrahydropyrimid-4-one-2yl, imidazol-2yl, 5-amino 1,2,4-triazol-4-yl, dihydroimidazol-2yl, amino(imino), pyridyl-urea or benzyl-urea.

3. Compounds of Claim 2 wherein G is pyridin-2yl, imidazolyl-2yl, 5-amino 1,2,4-triazol-4-yl, or tetrahydropyrimidinyl.

25 4. Compounds of Claim 1 wherein R₁ and R₂ are hydrogen.

5. Compounds of Claim 1 wherein R₃ is hydrogen, phenyl, or pyridyl.

6. Compounds of Claim 1 wherein R₄ is hydrogen or HNSO₂phenyl, HNSO₂alkyl or NHCO₂benzyl or NHCO₂neopentyl, NHCO₂adamantyl, NHCO₂CH₂adamantyl, NHCONHphenyl, NHCONHbenzyl, NHCONHalkyl, NHCOphenyl, NHCObenzyl,

30 NHCOalkyl, NHCOadamantyl.

7. Compounds of Claim 1 wherein G is pyridin-2yl, 6-aminopyridin-2yl, 5-amino 1,2,4-triazol-4-yl or imidazol-2yl or dihydroimidazol-2yl or tetrahydropyrimidin-2yl, R₁, R₂ and R₃ are hydrogen, R₄ is NHSO₂phenyl, NHCO₂benzyl, NHCO₂neopentyl and R₅ is hydrogen or alkyl of 1 to 3 carbon atoms.

5 8. Compounds of Claim 1 wherein G is pyridin-2yl, 6-aminopyridin-2yl 5-amino 1,2,4-triazol-4yl, imidazol-2yl, dihydroimidazol-2yl, or tetrahydropyrimidin-2yl, R₁, R₂ and R₄ are hydrogen, R₃ is phenyl or pyridyl and R₅ is hydrogen or alkyl of 1 to 4 carbon atoms.

9. Compounds of Claim 1 wherein n is 2 or 3.

10 10. A compound of Claim 1 where G is 1,4,5,6-tetrahydropyrimidyl and R₄ is NHCO₂R₉.

11. A compound of Claim 1, which is:

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(methoxycarbonyl)amino]propanoic acid;

15 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(propoxycarbonyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;

25 (2S)-2-{{(allyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{{(but-3-enyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

30 (2S)-2-{{(hexyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{{(octyloxy)carbonyl}amino}propanoic acid;

-127-

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;

5 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(butoxycarbonyl)amino]propanoic acid;

10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(isobutoxycarbonyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid; or

15 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid, or pharmaceutical salts thereof.

20 12. A compound of Claim 1 wherein G is 1,4,5,6-tetrahydropyrimidyl and R₄ is NHCONHR₉.

13. A compound of Claim 1 which is:

25 (2S)-2-{[(butylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{[(hexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

30 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-{[(octylamino)carbonyl]amino}propanoic acid;

(2S)-2-{[(allylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

35 (2S)-2-{[(1-adamantylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

40 (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

45

-128-

- (2S)-2-{{(benzylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 5 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid;
- 10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(2-methoxyanilino)carbonyl]amino}propanoic acid;
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(4-methoxyanilino)carbonyl]amino}propanoic acid;
- 15 (2S)-2-{{(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{{(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 20 (2S)-2-{{([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid
- (2S)-2-{{([1,1'-biphenyl]-2-ylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid
- 25 (2S)-2-{{(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid; or
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(1-naphthylamino)carbonyl]amino}propanoic acid or pharmaceutical salts thereof.
- 30
- 14. A compound of Claim 1 wherein G is 1,4,5,6-tetrahydropyrimidyl and R₄ is NHCOR₉.
- 35 15. A compound of Claim 1 which is:
- (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{{(2-phenylethyl)amino]carbonyl]amino}propanoic acid;
- 40 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-(isobutyrylamino)propanoic acid;
- (2S)-2-(hexanoylamino)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;
- 45

-129-

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-(pentanoylamino)propanoic acid;

5 (2S)-2-[(3,3-dimethylbutanoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-[(cyclohexylcarbonyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

10 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid;

15 (2S)-2-[(2-cyclohexylacetyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

20 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]-benzoyl}amino)-2-{[(E)-3-phenylprop-2-enoyl]amino}propanoic acid;

(2S)-2-[(2-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

25 (2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methylbenzoyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(2-methoxybenzoyl)amino]propanoic acid;

30 (2S)-2-[(4-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methylbenzoyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}-amino)-2-[(4-methoxybenzoyl)amino]propanoic acid;

40 (2S)-2-[(2,5-dimethyl-3-furoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-[(2-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

45

-130-

(2S)-2-[(4-bromobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

5 (2S)-2-[(2,3-dimethylbenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid; or

(2S)-2-[(3-chlorobenzoyl)amino]-3-({2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid or pharmaceutical salts thereof.

10 16. A compound of Claim 1 wherein G is pyrimidin-2-yl and R₄ is NHCO₂R₉.

17. A compound of Claim 1 which is:

15 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(phenoxy carbonyl)amino]propanoic acid;

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

20 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid;

25 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyphenoxy)carbonyl]amino}propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;

30 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;

35 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;

40 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-nitrobenzyl)oxy]carbonyl}amino)propanoic acid;

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

-131-

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid;

5 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methylphenoxy)carbonyl]amino}propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;

10 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;

15 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;

(2S)-2-{{(allyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid; or

20 (2S)-2-{{(but-3-enyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid or pharmaceutical salts thereof.

25 18. A compound of Claim 1 wherein G is pyrimidin-2-yl and R₄ is NHCONH₉.

19. A compound of Claim 1 which is:

30 (2S)-2-[(anilinocarbonyl)amino]-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{{(tert-butylamino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

35 (2S)-2-{{(butylamino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(4-methoxyanilino)carbonyl]amino}propanoic acid;

40 (2S)-2-{{(2-ethylanilino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{{(allylamino)carbonyl}amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

45

(2S)-2-{[(2,4-dichloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

5 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(2-toluidinocarbonyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid;

10 (2S)-2-{[(2-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{[(2-bromoanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

15 (2S)-2-{[[[1,1'-biphenyl]-2-ylamino]carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{[(4-fluorophenyl)-2-ylamino]carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

20 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-[(4-toluidinocarbonyl)amino]propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethyl)anilino]carbonyl}amino)propanoic acid;

25 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-({[4-(trifluoromethoxy)anilino]carbonyl}amino)propanoic acid;

(2S)-2-{[(4-chloroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

30 (2S)-2-{[(4-fluoroanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{[(4-acetylanilino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

35 (2S)-2-({[4-(ethoxycarbonyl)anilino]carbonyl}amino)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)propanoic acid;

40 (2S)-3-({2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl}amino)-2-{[(1-naphthylamino)carbonyl]amino}propanoic acid;

(2S)-2-{[(benzylamino)carbonyl]amino}-3-{[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl]amino}propanoic acid;

5 (2S)-3-{[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl]amino}-2-{[(2-phenylethyl)amino]carbonyl}amino}propanoic acid; or

(2S)-3-{[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]benzoyl]amino}-2-{[(octylamino)carbonyl]amino}propanoic acid or pharmaceutical salts thereof.

10

20. A compound of Claim 1 wherein G is 4,5-dihydro-1H-imidazolyl and R₄ is NHCO₂R₉.

15 21. A compound of Claim 1 which is:

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid;

20 (2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(methoxycarbonyl)amino]propanoic acid};

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(ethoxycarbonyl)amino]propanoic acid};

25

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(propoxycarbonyl)amino]propanoic acid};

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(isopropoxycarbonyl)amino]propanoic acid};

30

(2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid;

35 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]amino}propanoic acid;

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid;

40

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(hexyloxy)carbonyl]amino}propanoic acid;

(2S)-3-{[4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl]-amino}-2-{[(octyloxy)carbonyl]amino}propanoic acid;

45

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;

5 (2S)-2-[(butoxycarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

10 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid;

15 22. A compound of Claim 1 wherein G is 4,5-dihydro-1H-imidazolyl and R₄ is NHCONHR₉.

23. A compound of Claim 1 which is:

(2S)-2-{[(butylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(hexylamino)carbonyl]amino}propanoic acid;

25 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(octylamino)carbonyl]amino}propanoic acid;

(2S)-2-{[(allylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

30 (2S)-2-{[(cyclohexylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-2-{[(benzylamino)carbonyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

35 3-({4-[2-(2,5-dihydro-1H-imidazol-4-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-N-([(1S, 2R)-2-phenylcyclopropyl]amino)carbonyl)alanine;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-{[(2-methoxyanilino)carbonyl]amino}propanoic acid;

40 (2S)-2-{[(1,1'-biphenyl)-2-ylamino]carbonyl}amino)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid; or

-135-

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-({[(2-phenylethyl)amino]carbonyl}amino)propanoic acid or pharmaceutical salts thereof.

5 24. A compound of Claim 1 wherein G is 4,5-dihydro-1H-imidazolyl and R₄ is NHCOR₉.

10 25. A compound of Claim 1 which is:

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(isobutyrylamino)propanoic acid;

15 (2S)-2-(butyrylamino)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(hexanoylamino)propanoic acid;

20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pentanoylamino)propanoic acid;

25 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3,3-dimethylbutanoyl)amino]propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid;

30 (2S)-2-{[2-(1-adamantyl)acetyl]amino}-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-(pent-4-ynoylamino)propanoic acid;

35 (2S)-2-[(cyclohexylcarbonyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

40 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(2-phenylacetyl)amino]propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(3-phenylpropanoyl)amino]propanoic acid;

45 (2S)-2-[(2-cyclohexylacetyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}-amino)-2-[(E)-3-phenylprop-2-enoyl]amino}propanoic acid;

5 (2S)-2-[(2-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2-methylbenzoyl)amino]propanoic acid;

10 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2-methoxybenzoyl)amino]propanoic acid;

(2S)-2-[(4-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

15 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(4-methylbenzoyl)amino]propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(4-methoxybenzoyl)amino]propanoic acid;

20 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(4-methoxybenzoyl)amino]propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid;

25 (2S)-2-[(2-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-2-[(4-bromobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

30 (2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)-2-[(2,3-dimethylbenzoyl)amino]propanoic acid; or

35 (2S)-2-[(3-chlorobenzoyl)amino]-3-({4-[2-(4,5-dihydro-1H-imidazol-2-ylamino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid or pharmaceutical salts thereof.

40 26. A compound of Claim 1 wherein G is 3,4,5,6-tetrahydro-2H-azepinyl and R₄ is NHCO₂R₉.

27. A compound of Claim 1 which is:

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

45

-137-

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;

5 (2S)-2-[(ethoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;

10 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(isopropoxycarbonyl)amino]propanoic acid;

(2S)-2-{{(allyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

15 (2S)-2-{{(but-3-enyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

(2S)-2-{{(hexyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

20 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{{(prop-2-nyloxy)carbonyl}amino}propanoic acid;

(2S)-2-{{(octyloxy)carbonyl}amino}-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid;

25 (2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-{{(neopentyloxy)carbonyl}amino}propanoic acid;

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}-amino)-2-{{(2,2,2-trichloroethoxy)carbonyl}amino}propanoic acid;

30 (2S)-2-[(butoxycarbonyl)amino]-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)propanoic acid; or

(2S)-3-({2-hydroxy-4-[2-(3,4,5,6-tetrahydro-2H-azepin-7-ylamino)ethoxy]benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid or
40 pharmaceutical salts thereof.

28. A compound of Claim 1 wherein G is NH₂C(NH)- and R₄ is NHCO₂R₅.

29. A compound of Claim 1 which is:

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(benzyloxy)carbonyl]amino}propanoic acid;

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(methoxycarbonyl)amino]propanoic acid;

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(ethoxycarbonyl)amino]propanoic acid;

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(propoxycarbonyl)amino]propanoic acid;

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(isopropoxycarbonyl)amino]propanoic acid;

25 (2S)-2-{[(allyloxy)carbonyl]amino}-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-
2-hydroxybenzoyl]amino}propanoic acid;

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(butoxycarbonyl)amino]propanoic acid;

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(neopentyloxy)carbonyl]amino}propanoic acid;

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(hexyloxy)carbonyl]amino}propanoic acid;

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(prop-2-nyloxy)carbonyl]amino}propanoic acid;

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{([(1,1'-biphenyl]-2-ylmethoxy)carbonyl]amino}propanoic acid;

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-bromobenzyl)oxy]carbonyl}amino)propanoic acid;

(2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-fluorobenzyl)oxy]carbonyl}amino)propanoic acid;

5 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-bromobenzyl)oxy]carbonyl}amino)propanoic acid; or

10 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-(trifluoromethyl)benzyl)oxy]carbonyl}amino]propanoic acid or pharmaceutical
salts thereof.

15 30. A compound of Claim 1 wherein G is NH₂(NH)- and R₄ is NHCONHR₉.

31. A compound of Claim 1 which is:

15 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[
{(2-toluidinocarbonyl)amino}propanoic acid;

20 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-methoxyanilino)carbonyl]amino}propanoic acid;

25 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-chloroanilino)carbonyl]amino}propanoic acid;

30 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2-bromoanilino)carbonyl]amino}propanoic acid;

35 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(1,1'-biphenyl)-2-ylamino]carbonyl}amino}propanoic acid;

40 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-chloroanilino)carbonyl]amino}propanoic acid;

45 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-(trifluoromethoxy)anilino)carbonyl]amino}propanoic acid;

50 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-chloroanilino)carbonyl]amino}propanoic acid;

55 (2S)-3-{[4-(2-{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(4-fluoroanilino)carbonyl]amino}propanoic acid;

60 (2S)-2-[(4-acetylaniino)carbonyl]amino)-3-{[4-(2-{[amino(imino)methyl]-
amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(cyclohexylamino)carbonyl]amino}propanoic acid;

5 (2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(1-naphthylamino)carbonyl]amino}propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(benzylamino)carbonyl]amino}propanoic acid;

10 (2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-phenylethyl)amino]carbonyl]amino}propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(octylamino)carbonyl]amino}propanoic acid;

15 (2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxyanilino)carbonyl]amino}propanoic acid; or

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(anilinocarbonyl)amino]propanoic acid or pharmaceutical salts thereof.

32. A compound of Claim 1 wherein G is NH₂(NH)- and R₄ is NHCOR₉.

33. A compound of Claim 1 which is:

25 (2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]-amino}-2-(isobutyrylamino)propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
30 (butyrylamino)propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
35 (hexanoylamino)propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
40 (pentanoylamino)propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
45 [(3,3-dimethylbutanoyl)amino]propanoic acid;

(2S)-3-{[4-(2-{{amino(imino)methyl}amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
45 [(2,2,3,3-tetramethylcyclopropyl)carbonyl]amino}propanoic acid;

(2S)-2-{{[2-(1-adamantyl)acetyl]amino}-3-{[4-(2-{{amino(imino)methyl}amino}-
45 ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(pent-4-ynoylamino)propanoic acid;

5 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(cyclohexylcarbonyl)amino]propanoic acid;

10 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-phenylacetyl)amino]propanoic acid;

15 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-phenylpropanoyl)amino]propanoic acid;

20 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-cyclohexylacetyl)amino]propanoic acid;

25 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(E)-3-phenylprop-2-enoyl]amino]propanoic acid;

30 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-chlorobenzoyl)amino]propanoic acid;

35 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-methylbenzoyl)amino]propanoic acid;

40 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-methoxybenzoyl)amino]propanoic acid;

45 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(pyridin-3-ylcarbonyl)amino]propanoic acid;

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,5-dimethyl-3-furoyl)amino]propanoic acid;

-142-

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2-bromobenzoyl)amino]propanoic acid;

5 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-bromobenzoyl)amino]propanoic acid;

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(2,3-dimethylbenzoyl)amino]propanoic acid;

10 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(3-chlorobenzoyl)amino]propanoic acid;

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-(benzoylamino)propanoic acid;

15 (2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-ethylbenzoyl)amino]propanoic acid; or

(2S)-3-{[4-(2-{{[amino(imino)methyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(4-butoxybenzoyl)amino]propanoic acid or pharmaceutical salts thereof.

20

34. A compound of Claim 1 wherein G is R₈NHCO-, R₈ is benzyl and R₄ is NHCO₂R₉.

35. A compound of Claim 1 which is:

25

(2S)-3-{[4-(2-{{(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{(benzyloxy)carbonyl]amino}propanoic acid;

30

(2S)-3-{[4-(2-{{(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(methoxycarbonyl)amino]propanoic acid;

(2S)-3-{[4-(2-{{(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(ethoxycarbonyl)amino]propanoic acid;

35

(2S)-3-{[4-(2-{{(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(propoxycarbonyl)amino]propanoic acid;

(2S)-3-{[4-(2-{{(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-[(isopropoxycarbonyl)amino]propanoic acid;

40

(2S)-2-{{(allyloxy)carbonyl]amino}-3-{[4-(2-{{(benzylamino)carbonyl]-amino}ethoxy)-2-hydroxybenzoyl]amino}propanoic acid;

45

(2S)-3-{[4-(2-{{(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-{{(but-3-enyloxy)carbonyl]amino}propanoic acid;

-143-

(2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(prop-2-nyloxy)carbonyl]amino}propanoic acid;

5 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(hexyloxy)carbonyl]amino}propanoic acid;

10 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(octyloxy)carbonyl]amino}propanoic acid;

15 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;

20 (2S)-3-{[4-(2-{[(benzylamino)carbonyl]amino}ethoxy)-2-hydroxybenzoyl]amino}-2-
[(butoxycarbonyl)amino]propanoic acid; or

25 36. A compound of Claim 1 wherein G is R₈NHCO, R₈ is pyridin-3-yl methyl, and
R₄ is NHCO₂R₉.

37. A compound of Claim 1 which is:

30 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(pyridin-3-
ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;

35 (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-
ethoxy]benzoyl}amino)-2-[(methoxycarbonyl)amino]propanoic acid;

40 (2S)-2-[(ethoxycarbonyl)amino]-3-{(2-hydroxy-4-[2-({[(pyridin-3-
ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;

45 (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)-
ethoxy]benzoyl}amino)-2-[(propoxycarbonyl)amino]propanoic acid;

(2S)-2-{[(allyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(pyridin-3-
ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;

-144-

(2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino}propanoic acid;

5 (2S)-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid;

(2S)-2-{[(hexyloxy)carbonyl]amino}-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino}propanoic acid;

10 (2S)-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;

15 (2S)-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;

(2S)-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;

20 (2S)-2-[(butoxycarbonyl)amino]-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino}propanoic acid; or

(2S)-3-{[2-hydroxy-4-[2-({[(pyridin-3-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(isobutoxycarbonyl)amino]propanoic acid or pharmaceutical salts thereof.

25 38. A compound of Claim 1 wherein G is R₈NHCO and R₈ is pyridin-4-yl and R₄ is NHCO₂R₉.

30 39. A compound of Claim 1 which is:

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-{[2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino}propanoic acid;

35 (2S)-3-{[2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(methoxycarbonyl)amino]propanoic acid;

(2S)-2-{[(ethoxycarbonyl)amino]-3-{[2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino}propanoic acid;

40 (2S)-3-{[2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(propoxycarbonyl)amino]propanoic acid;

(2S)-3-{[2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(isopropoxycarbonyl)amino]propanoic acid;

-145-

- (2S)-2-{[(allyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- 5 (2S)-2-{[(but-3-enyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(prop-2-nyloxy)carbonyl]amino}propanoic acid;
- 10 (2S)-2-{[(hexyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(octyloxy)carbonyl]amino}propanoic acid;
- 15 (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(neopentyloxy)carbonyl]amino}propanoic acid;
- 20 (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-{[(2,2,2-trichloroethoxy)carbonyl]amino}propanoic acid;
- (2S)-2-[(butoxycarbonyl)amino]-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid; or
- 25 (2S)-3-{(2-hydroxy-4-[2-({[(pyridin-4-ylmethyl)amino]carbonyl}amino)ethoxy]-benzoyl}amino)-2-[(isobutoxycarbonyl)amino]propanoic acid or pharmaceutical salts thereof.

40. A compound of Claim 1 which is:

- 30 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(4-methylbenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(2-hydroxy-4-[2-({[(4-methoxybenzyl)amino]carbonyl}amino)ethoxy]benzoyl}amino)propanoic acid;
- 35 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(4-[2-({[(4-chlorobenzyl)amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(4-[2-({[(4-dimethylamino)benzyl]amino}carbonyl)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;
- 40 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-{(4-{2-[(4-(aminosulfonyl)benzyl]amino)carbonyl}amino)ethoxy}-2-hydroxybenzoyl}amino)propanoic acid;
- (2S)-3-{(4-{2-[(4-(aminosulfonyl)benzyl]amino)carbonyl}amino)ethoxy}-2-hydroxybenzoyl}amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid;

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(2-hydroxy-4-[2-[(4-(trifluoromethoxy)-benzyl]amino)carbonyl]amino]ethoxy]benzoyl]amino]propanoic acid;

5 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-((2-chlorobenzyl)amino)carbonyl]-amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((2-methylbenzyl)-amino]carbonyl]amino)ethoxy]benzoyl}amino)propanoic acid;

10 (2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-((2-bromobenzyl)-amino]carbonyl}amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({4-[2-((2,4-dichlorobenzyl)amino)-carbonyl]amino)ethoxy]-2-hydroxybenzoyl}amino)propanoic acid;

15 (2S)-3-({4-[2-((2-aminobenzyl)amino)carbonyl]amino)ethoxy]-2-hydroxybenzoyl}-amino)-2-{[(benzyloxy)carbonyl]amino}propanoic acid; or

(2S)-2-{[(benzyloxy)carbonyl]amino}-3-({2-hydroxy-4-[2-((pyridin-2-ylmethyl)amino)carbonyl]amino)ethoxy]benzoyl}amino)propanoic acid or pharmaceutical salts thereof.

41. A compound of Claim 1 which is:

25 (2S)-2-Benzenesulfonylamino-3-(2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid;

(2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid tert-butyl ester;

30 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(pyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid;

35 3-{2-Hydroxy-5-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxyl-benzoylamino)-3-phenyl-propionic acid ethyl ester;

(2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino}-propionic acid 2-(2-tert-butoxycarbonylamino-ethoxy)-ethyl ester;

40 (2S)-2-Benzenesulfonylamino-3-{2-hydroxy-5-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-butoxy]-benzoylamino}-propionic acid ethyl ester;

(2S)-2-Benzenesulfonylamino-3-{2-hydroxy-4-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino}-propionic acid;

45

3-[2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]-benzoylamino]-3-phenyl-propionic acid;

5 (2S)-2-{Adamantan-1-yloxycarbonylamino)-3-[2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxy]-benzoylamino)-propionic acid;

(2S)-2-Benzenesulfonylamino-3-[2-hydroxy-4-[3-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-propoxy]-benzoylamino)-propionic acid ethyl ester;

10 3-[2-Hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy)-benzoylamino)-3-phenyl-propionic acid ethyl ester;

(2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-[2-hydroxy-4-[2-(1,4,5,6-tetrahydro-pyrimidin-2-ylamino)-ethoxyl]-benzoylamino)-propionic acid;

15 (2S)-2-Benzenesulfonylamino-3-[2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino)-propionic acid isopropyl ester;

20 (2S)-2-tert-Butoxycarbonylamino-3-[2-hydroxy-4-[2-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-ethoxy]-benzoylamino)-propionic acid; or

(2S)-2-Benzenesulfonylamino-3-[2-hydroxy-5-[4-(1,4,5,6-tetrahydropyrimidin-2-ylamino)-butoxy]-benzoylamino)-propionic acid or pharmaceutical salts thereof.

25

42. A compound of Claim 1, which is:

2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester;

2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid;

30 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride;

2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydrochloride;

35 2(S)-Benzylloxycarbonylamino-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid ethyl ester hydrochloride;

-148-

2(S)-Benzylcarbamoylaminocarbonyl-3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid hydrochloride;

3-[4-(2-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride;

5 3-[4-Guanidinoethoxy)-2-hydroxy-benzoylamino]-3-phenylpropanoic acid hydrochloride;

3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester;

10 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ;

3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid ethyl ester dihydro-chloride;

3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-pyridin-3-yl-propanoic acid;

15 3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid ethyl ester dihydrochloride;

3-[4-(2-Guanidino-ethoxy)-2-hydroxybenzoyl-amino]-3- pyridin-3-yl-propanoic acid;

20 3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester;

3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]-3-phenyl-propanoic acid hydrochloride;

3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-phenyl-propanoic acid ethyl ester hydrochloride;

25 3-[2-hydroxy-4-[2-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)ethoxy]benzoylamino]-3-phenyl-propanoic acid;

-149-

3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]benzoylamino]-3-phenylpropanoic acid ethyl ester;

3-[2-hydroxy-5-[3-(pyrimidin-2-ylamino)-propoxy]benzoylamino]-3-phenylpropanoic acid;

5 3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]benzoylamino]-3-phenylpropanoic acid ethyl ester hydrochloride;

3-[2-hydroxy-5-[3-(3,4,5,6-tetrahydro-pyrimidin-2-ylamino)propoxy]benzoylamino]-3-phenylpropanoic;

10 2(S)-Benzoyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ethyl ester hydrochloride;

2(S)-Benzoyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)-ethoxy]benzoylamino]propionic acid methyl ester;

2(S)-Benzoyloxycarbonylamino-3-[2-hydroxy-4-[2-(pyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid ;


15 2(S)-Benzenesulfonylamino-3-[2-hydroxy-4-(2-methyl-pyrimidin-2-ylamino)ethoxy]benzoylamino]propionic acid; or

2-Amino-3-[2-hydroxy-4-[2-(3,4,5,6-tetra-hydropyrimidin-2-ylamino)ethoxy]-benzoylamino]propionic acid dihydrochloride or pharmaceutical salts thereof.

20 43. A pharmaceutical composition comprising a compound of Claim 1 and at least one pharmaceutically acceptable carrier or excipient.

44. A method of treating a mammal afflicted with a condition that is mediated by an integrin receptor which comprises administration to the mammal a compound of 25 the formula:


-150-



wherein:

G is

5



R¹ and R² are independently, hydrogen, alkyl of 1 to 6 carbon atoms, mono or bicyclic aralkyl of 6 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

10

R³ is hydrogen, mono or bicyclic aryl of 6 to 10 carbon atoms, 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and
15 O;

R⁴ is hydrogen, NHR⁹, OR⁹, NHCO₂R⁹, NHCONHR⁹, NHCOR⁹ or NHSO₂R⁹;
provided that R³ and R⁴ are not both hydrogen;

20 R⁵ is hydrogen, or alkyl of 1 to 6 carbon atoms, optionally substituted with a terminal group forming a prodrug;

R⁶ and R⁷ are hydrogen, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, or aralkoxy of 6 to 10 carbon atoms;

-151-

R⁸ and R⁹ are independently hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbons, alkynyl of 2 to 10 carbons, mono or polycycloalkyl of 3-10 carbon atoms, mono or bicyclic aryl of 6 to 10 carbon atoms, 6 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O, mono or
5 bicyclic aralkyl of 7 to 10 carbon atoms, or heterocycloalkyl-alkyl comprised of a 5 to 10 membered mono or bicyclic heterocycloalkyl having 1 to 3 heteroatoms selected from S, N and O and an alkyl of 1 to 6 carbon atoms;

10

45. The method of Claim 44 wherein the integrin receptor is α_vβ₃.
46. The method of Claim 44 wherein the condition is cancer.
47. The method of Claim 46 wherein the cancer is associated with at least one of metastasis, angiogenesis, neovascularization and tumor growth.
- 15 48. The method of Claim 44 wherein the condition is benign tumor growth.
49. The method of Claim 44 wherein the condition is neovascularization.
50. The method of Claim 49 wherein neovascularization is associated with diabetic retinopathy, glaucoma, macular degeneration or blindness.
51. The method of Claim 49 wherein neovascularization is associated with
20 rheumatoid arthritis.
52. The method of Claim 44 wherein the condition is inflammation.
53. The method of Claim 52 wherein the inflammation is associated with rheumatoid arthritis or psoriasis.
54. The method of Claim 44 wherein the condition is restenosis.
- 25 55. The method of Claim 54 wherein restenosis is associated with at least one of smooth muscle cell migration, smooth muscle cell proliferation, vascular endothelial cell migration and vascular endothelial cell proliferation.
56. The method of Claim 44 wherein the condition is viral infection.

-152-

57. The method of Claim 56 wherein the viral infection is caused by an adenovirus.
58. The method of Claim 44 wherein the condition is characterized by bone resorption.
59. The method of Claim 58 wherein bone resorption is associated with osteoporosis, Paget's disease, hypercalcemia, osteopenia, hyperparathyroidism, periarticular erosions, and periodontal disease.

INTERNATIONAL SEARCH REPORT

Int	ional Application No
PCT/US 99/08180	

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6	C07D239/12	C07D407/12	C07D239/42	C07D207/22	C07D223/12
	C07C279/14	C07D213/81	C07D213/82	C07D307/68	C07C275/16
	C07D403/12	A61K31/505	A61K31/41	A61K31/155	A61K31/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 32710 A (MERCK & CO., INC.) 7 December 1995 (1995-12-07) cited in the application claims 1-25 ---	1-59
Y	WO 95 13262 A (RHONE-POULENC RORER LTD.) 18 May 1995 (1995-05-18) cited in the application claims 1-47 ---	1-59
A	WO 97 08145 A (G. D. SEARLE & CO.) 6 March 1997 (1997-03-06) cited in the application claims 1-58 ---	1-59
A	EP 0 820 988 A (HOECHST AG & GENENTECH, INC.) 28 January 1998 (1998-01-28) claims 1-10 ---	1-59 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the International search report
29 July 1999	10/08/1999
Name and mailing address of the ISA European Patent Office, P.O. Box 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Herz, C

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/08180

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 820 991 A (HOECHST AG & GENENTECH, INC.) 28 January 1998 (1998-01-28) claims 1-11 ---	1-59
A	EP 0 796 855 A (HOECHST AG) 24 September 1997 (1997-09-24) claims 1-8 ---	1-59
A	WO 98 08840 A (MERCK & CO., INC.) 5 March 1998 (1998-03-05) claims 1-33 -----	1-59

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/08180

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9532710	A	07-12-1995		AU 701776 B AU 2586895 A CA 2190870 A EP 0760658 A JP 10501222 T US 5741796 A		04-02-1999 21-12-1995 07-12-1995 12-03-1997 03-02-1998 21-04-1998
WO 9513262	A	18-05-1995		AT 171158 T AU 8149894 A CA 2176363 A DE 69413414 D DE 69413414 T EP 0728128 A ES 2123941 T JP 9505043 T ZA 9409035 A		15-10-1998 29-05-1995 18-05-1995 22-10-1998 25-03-1999 28-08-1996 16-01-1999 20-05-1997 14-05-1996
WO 9708145	A	06-03-1997		AU 702487 B AU 7103996 A CA 2230209 A CN 1201454 A CZ 9800341 A EP 0850221 A NO 980817 A NZ 318926 A PL 325312 A		25-02-1999 19-03-1997 06-03-1997 09-12-1998 16-09-1998 01-07-1998 24-04-1998 29-04-1999 20-07-1998
EP 820988	A	28-01-1998		DE 19629817 A AU 2941997 A BR 9704071 A CA 2211148 A CN 1174836 A CZ 9702344 A HR 970405 A HU 9701265 A JP 10114751 A NO 973400 A NZ 328387 A PL 321253 A SK 100797 A		29-01-1998 05-02-1998 29-12-1998 24-01-1998 04-03-1998 18-03-1998 30-04-1998 28-05-1998 06-05-1998 26-01-1998 28-01-1999 02-02-1998 08-07-1998
EP 820991	A	28-01-1998		DE 19629816 A AU 2941897 A BR 9704072 A CA 2211270 A CZ 9702343 A HR 970404 A HU 9701264 A JP 11043476 A NO 973399 A NZ 328388 A PL 321254 A SK 100597 A		29-01-1998 05-02-1998 05-01-1999 24-01-1998 18-03-1998 30-04-1998 28-05-1998 16-02-1999 26-01-1998 28-07-1998 02-02-1998 04-02-1998
EP 796855	A	24-09-1997		DE 19626701 A DE 19635522 A AU 1638097 A BR 9701335 A		08-01-1998 05-03-1998 25-09-1997 18-08-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/08180

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 796855 A		CA	2199923 A	20-09-1997
		CZ	9700823 A	17-12-1997
		HR	970156 A	30-04-1998
		HU	9700602 A	30-03-1998
		JP	9255664 A	30-09-1997
		NO	971268 A	22-09-1997
		NZ	314433 A	29-03-1999
		PL	319071 A	29-09-1997
		SK	35097 A	08-10-1997
WO 9808840 A	05-03-1998	AU	4086597 A	19-03-1998